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1 Introduction 
1.1 Human aging 
Aging is an essential, inevitable, physiological complex phenomenon characterized by a 
progressive decline in the functional maintenance of tissue homeostasis and an expanding 
propensity to degenerative diseases and death (Cui et al., 2012). Even if this process is still not 
completely understood (Vitale et al., 2013), there is a large agreement on fact that the aging is: 
(1) universal; (2) intrinsic (i.e., “built-in”); (3) deleterious and (4) irreversible (Shokolenko et al., 
2014). Over time, different aging theories proposed a variety of such basic mechanisms in 
order to explain it (Shokolenko et al., 2014), even if, at the molecular level, many evidences 
suggest that damages to macromolecules are at the base of several of the most important 
mechanisms (Kirkwood, 2005). In particular, as summarized by López-Otín and colleagues in 
figure 1, the main phenomena thought to be among the causes of aging are: genomic damages 
due to both endogenous and environmental factors, which lead to genomic instability; 
epigenetic alterations that involve changes in DNA methylation patterns, post-translational 
modification of histones and chromatin remodelling; decline of stem cell regenerative 
potential; deregulation of nutrient sensing mediated by insulin and IGF-1 signalling pathway, 
mTOR, AMPK and sirtuins; decline in protein quality control and degradation systems 
(autophagy-lysosomal and ubiquitin-proteasome systems) and accumulation of oxidised cell 
components and indigested garbage; cellular senescence; telomere shortening; mitochondria 
dysfunction; altered intercellular communication particularly in relation to inflammation 
(López-Otínet al., 2013). 
 
Figure 1: The 9 hallmarks of aging (Lopez-Otin et al., 2013). 
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These hallmarks of aging can be modulated by circulatory factors (Kennedy et al., 2014), 
between which, there are IL-6, IL-18 and C-reactive protein, that are pro-inflammatory 
molecules whose levels increase with age in both women and men (Howcroft et al., 2013). 
Elevated levels of inflammatory biomarkers, such as the above mentioned, are predictive and 
associated with the age-related phenotype, diseases and mortality (Franceschi and Campisi, 
2014). In particular, Franceschi and colleagues found that a low-grade, chronic, systemic 
inflammatory status exists in absence of overt infection and characterizes the aging process. 
They named this status “Inflamm-aging” (Franceschi et al., 2000), it is provoked by continuous 
antigenic load and stress, with the persistence of inflammatory stimuli over time (Morrisette-
Thomas et al., 2014) and in particular by an impairment of the balance between pro-
inflammatory and anti-inflammatory agents (Cevenini et al., 2013), as well as the activation of 
macrophages and the expansion of specific clones of T lymphocytes directed toward common 
antigens (Franceschi et al., 2000). However, the identification of pathways involved in the 
control of age-related inflammation across multiple system is very important, above all 
because several mechanisms of chronic inflammation could be implicated. Among others, it 
can be recognized: (i) constant production of reactive molecules by infiltrating leukocytes, that 
at the end damages the structural and cellular components of tissues; (ii) amplification of 
inflammatory response due to damaged non-immune cells and activated immune cells and (iii) 
interference with “anabolic signalling” (Franceschi and Campisi, 2014). Moreover, from the 
fields of genetics, epigenetics, proteomics and other “omics” platforms, new experimental 
data come to demonstrate that others cellular processes are involved, also of non-
immunological nature, such as microRNAs (miRs), agalactosylated N-glycans, gut microbiota-
related products and metabolites, cellular senescence, mitochondrial function and reactive 
species production (Santoro et al., 2014).  
These latter processes are also the principal actors of two of the most important aging theories 
proposed and for this reason, will be discussed in more detail below (see section 1.2 and 1.3). 
On the whole, the aging of human body could be considered as a mosaic (Cevenini et al., 2008) 
because the different tissues could age at different rates and likely with slightly different 
mechanisms thus differently contributing to inflammaging. Hereafter it is summarized the 
knowledge of the aging process in liver, muscle and adipose tissues, which are the object of 
the study in this thesis, with particular attention to mitochondria and telomeres. 
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1.1.1 Human liver aging 
 
Figure 2: Liver in human body (http://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0018957/). 
Liver is a vital organ supporting a multitude of different functions and playing a central role in 
human physiology. In particular, among other functions, the liver represents the main 
reservoir of blood in the body and hepatocytes are assigned to the synthesis of bile, as well as 
to the control of levels of circulating lipids, carbohydrates and amino acids, to the removal of 
toxins from the blood and to the assimilation of nutrients and liposoluble vitamins (A, D, K and 
E), that can be also stored in the liver (Martini et al., 2008).  
Besides, one of the most important liver characteristic is that it is able to regenerate itself after 
suffering several injuries, but during aging the ability to withstand a hepatic insult is reduced 
(Hoare et al., 2010). Indeed, studies in rodents and humans show as some structural changes 
in liver morphology occur (Schmucker and Sanchez, 2011): (a) the volume of hepatocytes 
declines with senescence and also the relative volumes of hepatocyte organelles change 
during ageing (Hoare et al., 2010), (b) the smooth surfaced of endoplasmic reticulum is 
progressively lost, (c) the volume of the dense body compartment, for example, secondary 
lysosomes, residual bodies, or lipofuscin increases, as well as (d) the hepatocyte polyploidy 
increases (Schmucker, 1990). In spite of this, liver function tests failed to identify significant 
age-related deficits (Schmucker and Sanchez, 2011).  
Additionally, in the last years it is notably increased the number of orthotopic liver transplants 
where the age of the donor is considerably higher than that of the recipient. Clinical data, in 
fact, point out how, in some conditions, function and duration of liver graft from aged subjects 
are comparable to those achievable with liver grafts from young donors (Cescon et al., 2003, 
2008;). Therefore a peculiar aging pattern for liver seems to emerge from this evidence 
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(Conboy et al., 2005; Bellavista et al., 2014), but the molecular mechanisms involved are still 
largely unknown (Bellavista et al., 2014).  
One hypothesis is that mitochondrial dysfunction might play a pivotal role. It was seen, indeed, 
that in liver, as well as in some other tissues, the activities of the electron transport chain 
protein complex are decreased with age and in liver this is particularly true for complex I and 
IV (Castro et al., 2012). Moreover, Navarro and colleagues suggest that the activities of 
complex I and IV are inversely correlated with the accumulation of oxidative damaged lipid, 
proteins and DNA (Navarro et al, 2002), that leads to a vicious circle and to more accumulation 
of mitochondrial dysfunction (Castro et al., 2012).  
As Muller-Hocker and colleagues suggested, also in liver the expression either of mitochondrial 
and nuclear encoded electron transporter chain complexes or the respiration rates are 
reduced during aging (Muller-Hocker et al., 1997) and these deficits probably are due to the 
oxidative mtDNA lesions occurring in aged liver, that if not repaired, may result in mtDNA 
deletion (Gredilla et al., 2010).  
The elevated mtDNA damage levels are consistent with the age-dependent rises in lipid 
peroxidation and thus in agreement with the age-associated accumulation of lipofuscin in the 
liver (Brunk and Terman, 2002), that reflects an inability to eliminate cellular waste products 
and compromised normal cell activities (Schmucker and Sachs, 2002). 
1.1.2 Human skeletal muscle aging 
In human body, skeletal muscle is the most abundant tissue, accounting for almost 40% of the 
total body mass. It is also a major site of metabolic activity and, in healthy conditions, carries 
out an important role in the prevention of metabolic disorders, such as obesity, diabetes and 
hypertension, among others (Romanello and Sandri, 2010). Changes in exercise, loading, 
nutrition and hormones are factors able to induce a muscle answer, since skeletal muscle is a 
plastic tissue able to respond and, above all, adapt to them (Sandri, 2008). This ability is 
attributable to contractile proteins located inside the muscle cells (myocytes), which 
determine the cellular size, morphology (Masiero and Sandri, 2010), but also different type of 
contraction and of movement abilities. Since ATP is required for muscle contraction, in muscle 
cells there are many mitochondria (Cogswell et al., 1993; Manneschi and Federico, 1995; 
Bizeau et al., 1998; Picard et al., 2013), that carry out vital functions in the maintenance of 
myocite viability, in particular in the context of energy provision, redox homeostasis and 
regulation of several catabolic pathways (Marzetti et al., 2013). Since the importance of these 
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organelles, it is possible that their dysfunction is implicated in the age-dependent muscle 
degeneration. 
In particular, the age-associated decline in skeletal muscle mass, strength and function is 
named “sarcopenia” (Roseberg, 1989) and it is referred to a complex medical condition that 
predicts a deficiency in mobility, disability, leading in turn to loss of independence, a higher 
risk of falls, reduced quality of life, increased health care costs and eventually an increased risk 
of mortality (Montero-Fernandez and Serra-Rexach, 2013). The reduction in size of type II 
fibers seems to be the main cause of sarcopenia (Nilwiket al., 2013), together with a decreased 
capacity of proliferation and differentiation of the muscle stem cells (satellite cells) that lead to 
diminished generation of myogenic fibers and a replacement of them with fibrous tissue 
(Verdijk et al., 2007; Gopinath and Rando, 2008; Sahin and De Pinho, 2010;).  
 
Figure 3: Sarcopenia is the age associated decline in muscle mass, strength and function, with an increment of 
muscle atrophy. (OpenStax College. Anatomy & Physiology. Connexions, June 19, 2013. 
http://cnx.org/content/col11496/1.6/) 
As previous anticipated, an increasing number of evidences suggest that mitochondrial 
dysfunction is the main responsible of age-related skeletal muscle decline (Johnson et al., 
2013), but the interpretation of the consequences is complicated by the presence of two 
population of mitochondria inside myocites: sub-sarcolemmal and inter-myofibrillar 
mitochondria (Johnson et al., 2013), with different specific biochemical and functional 
proprieties and, above all, a distinct behaviour during aging (Marzetti et al., 2013).  
Besides, in last years, increasing literature reports an accumulation with aging of fat between 
the fibres. This type of fat, named inter-muscular adipose tissue (IMAT), has been identified as 
a potential contributor to sarcopenia and to reduced mobility of the elderly. According to 
Marcus and colleagues, IMAT may also be metabolically active secreting, like inflammatory 
cytokines that contribute to systemic inflammation (Marcus et al., 2012). 
6 
 
1.1.3 Human white adipose tissue aging 
 
Figure 4: Adipose tissue is a connective tissue, consisting of fat cell with little extracellular matrix. (OpenStax 
College. Anatomy & Physiology. Connexions, June 19, 2013. http://cnx.org/content/col11496/1.6/)  
Two types of adipose tissue could be distinguished: brown adipose tissue, whose main role is 
thermogenesis, particularly in small mammals and human neonates, and white adipose tissue 
(WAT). The latter is composed by adipocytes, that are the most prevalent cell type, and many 
others, like the stromovascular fraction, which in turn is constituted from approximately 10% 
of CD14+CD31+ macrophages (Fantuzzi, 2005). In mammals and birds, WAT is the main site of 
energy storage, since substrate being deposited as triacylglycerols at a high energy density. 
Initially it was thought that this was the principal function of white adipose tissue, together 
with thermal and mechanical insulation, but now this tissue is seen as a highly dynamic organ, 
involved in several physiological and metabolic processes (Trayhurn and Wood, 2004). Indeed, 
WAT is an important source of cytokines, chemokines and adipocyte-specific factors, known as 
adipokines, that are used by WAT to regulate several biologic activities, like, among others, 
appetite, energy expenditure, insulin sensitivity, bone metabolism and the endocrine and 
reproductive system (Fantuzzi, 2005). In particular, WAT produces as much as 30% of 
circulating IL-6 and tumor necrosis factor, that increase its release in people with obesity 
(Vitale et al., 2013). In this way, WAT affects inflammation and immunity, as seen by Ostan and 
colleagues in a study on centenarians, where the healthy status of old people it is argued to be 
due by levels of adipokines (Ostan et al.,2008). Specifically, the production of inflammatory 
mediators is linked to oxidative stress and generation of reactive oxygen species, that are 
increased during hypoxia and that lead to a deregulated expression of adipokines and to 
induction of adipogenesis (Vitale et al., 2013). In fact, white adipose tissue in adults is 
increased, as result of adipocytes hypertrophy and hyperplasia. This is the reason why WAT is 
the only endocrine tissue that increase with age (Jackson et al., 2012). Moreover, the 
increment of adipose tissue is preferentially in its visceral component, but, above all, it is 
invaded by activated macrophages and T-cells, able in turn to induce the activation of multiple 
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signalling networks and the generation of inflammatory compounds. These are the principal 
responsible of a low-grade, chronic inflammation, orchestrated by metabolic cells in response 
to excess nutrients and energy, referred as “metaflammation” (Gregor and Hotamisligil, 2011). 
Classically it is thought that metaflammation occurs in young and adult (obese) people, while 
inflammaging occurs later in life even in non obese and lean people, but a possible overlapping 
of the two phenomena in the same individual cannot be excluded and it is an interesting 
perspective to purse (Cevenini et al., 2013), also because little is known about modifications of 
this peculiar endocrine tissue, as white adipose tissue is yet (Vitale et al., 2013).  
 
1.2 Mitochondria 
1.2.1  Mitochondria structure and function 
Mitochondria – from the Greek mitos (thread-like) and khondros (grain or granule) – are 
intracellular, bacteria-sized organelles present in all eukaryotic cells (Schon et al., 2012). They 
are bound by two lipid bilayer membranes (Okamoto and Kondo-Okamoto, 2012), with specific 
and different characteristics and functions. The outer mitochondrial membrane (OMM) is 
highly permeable, regulates the mitochondrial shape and contains enzymes involved in amino 
acids’ oxidation, fatty acids’ elongation, phospholipids biosynthesis and hydroxylases. Instead, 
the inner mitochondrial membrane (IMM) is characterised by some peculiar structures, called 
cristae. Cristae contain the electron transport proteins and in particular, the cytochromes that 
form the electron transport chain, and are associated to the five respiration complexes located 
in the mitochondrial matrix. Thus, each mitochondrion results divided in four distinct section: 
OMM, the inter-membrane space, IMM and the mitochondrial matrix, as shown in figure 5. 
 
Figure 5: Mitochondrial structure(http://mjlightfoot.edublogs.org/). 
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Inside the cells, mitochondria carry out many functions as iron/sulfur cluster biosynthesis, the 
synthesis of amino acids, lipid metabolism, copper homeostasis, signal transduction, 
thermogenesis and the control of apoptosis, among others (Peterson et al., 2012; Osiewacz 
and Bernhardt, 2013). Nevertheless, the main mitochondrial function is to produce energy, 
generating more than 90% of a typical cell adenosine triphosphate (ATP), which is used to 
drive all cellular energy-consuming processes (Schon et al., 2012, Osiewacz and Bernhardt, 
2013).  
Mitochondrial energy production is the result of two coordinated processes: the tricarboxylic 
acid (TCA) cycle, also known as the Kreb’s or the citric acid cycle, and the electron transport 
chain (ETC). The former produces only a small amount of ATP from carbohydrates and fats, 
since its main aim is to provide, from pyruvate generated by glycolysis, not ATP but coenzymes 
NADH and FADH for ETC. More specifically, the Kreb’s cycle consists of nine steps leading to 
the production of three molecules of NADH and two molecules of FADH, for a total of six 
molecules of NADH and four molecules of FADH per molecule of pyruvate. Furthermore, two 
molecules of ATP are generated during acetyl-CoA oxidation with two additional molecules of 
CO2 (Lehninger, 2004). 
 
Figure 6: Mitochondrial structure and energy production processes (Adapted from Lehninger, 2004 and Larsson, 
2010). 
The role of NADH and FADH is to carry electrons to the electron transport chain, whose 
reactions create a reduction potential that increases along the chain. In this way, the 
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generated energy is sufficient to drive the protons translocation across the IMM, creating a 
proton gradient and a membrane potential, collectively called the proton motive force, which 
drives the synthesis of ATP. This process, named also oxidative phosphorylation (OXPHOS), is 
not a perfect system since proton leakages occurs reducing the yields of ATP production 
(Mathews et al., 2004).  
1.2.2 Mitochondrial genome (mtDNA)  
A fundamental characteristic of mitochondria is that, as evolutionary relics of aerobic bacteria 
that invaded the proto-eukaryotic cell a billion of years ago, they have a separate genome 
(Green et al., 2011), that is maternally inherited (figure 7). The human mtDNA is a circular 
double strand DNA molecule of 16569bp (Anderson et al., 1981), present in multiple copies in 
each cell. They are organised in protein-DNA complexes (mitochondrial nucleoids) often 
associated to the inner mitochondrial membrane and that look like globular foci. Each mtDNA 
molecule can be divided in two regions. The former is a regulatory region (16024-576bp), 
named displacement loop (D-loop) and involved in the replication and transcription processes, 
since it contains transcriptional promoters and replication origins. The second one is the 
coding region (577-16023bp), containing only 37 genes, 13 of which encoding for proteins 
which are part of the core subunits of the respiratory complexes I, III, IV and V, the others 
encoding for 2 rRNAs (12S and 16S) and 22 tRNAs necessary for mtDNA translation (Ylikallio et 
al., 2010). Moreover, the strands of the duplex DNA can be distinguished on the basis of G+C 
content in heavy (H, G-rich) and light (L, C-rich) strands (Kasamatsu et al., 1974). Most of the 
information is encoded on the H strand, that includes 2 rRNAs, 14 tRNAs and 12 polypeptides, 
while the L strand codes for only 8 tRNAs and one polypeptide. 
 
Figure 7: Mitochondrial genome (St John, 2012)  
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1.2.2.1 Replication models of mtDNA 
It is known that each cell contains numerous mitochondria and that each of them contains 
several hundreds to thousands copies of mtDNA, probably due to the faster evolution of 
mtDNA in respect to nuclear DNA (Kato, 2001). Therefore, replication of mtDNA is essential to 
the maintenance of the mtDNA copy number per cell, but there is any agreement about how 
mitochondrial DNA replicates itself. For this reason, three main models have been proposed 
(figure 8). The strand-displacement model is the first, proposing that the synthesis of H strand 
initiates at the OH origin within the D-loop and proceeds continuously. Continuing the H strand 
synthesis, replication intermediates progressively distance from the parental H stand 
maintained in a single stranded form, while the L strand synthesis begins at about two thirds of 
the distance around the genome, when the OL get exposed, and proceeds continuously 
(Kasamatsu and Vinograd, 1973). The second model is the strand-coupled model and it is 
based on what happen during DNA replication in bacteria, with the presence of fully double-
stranded DNA theta-like replication intermediates which are indicative of coupled H and L 
strand synthesis and of a bidirectionally progression of the replication. The progression ends 
within the D-loop region (Holt et al.,2000). Finally, the third model proposed is that referred to 
as RITOLS (RNA Incorporated Through Out the Lagging Strand) (Yasukawa et al., 2006). It 
suggests that during mtDNA replication, RNA is incorporated throughout the H strand and 
implies strand-coupled replication proceeding unidirectionally from the D-loop region, with the 
RNA replication intermediates subsequently being maturated into DNA (Holt and Reyes, 2012; 
McKinney and Oliveira, 2013). 
 
Figure 8: mtDNA replication models (McKinney and Oliveira, 2013). 
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1.2.3 Mitochondrial Theory of Aging and mtDNA rearrangements 
Among the proposed theories of aging, one of the most popular is the Free 
Radical/Mitochondrial Theory of Aging (MTA), proposed by Harman in 1956. At the beginning, 
this theory postulated that the increase of reactive species of oxygen (ROS), that are generated 
in mitochondria as a “waste” of aerobic respiration and several other catabolic and anabolic 
processes, lead to damage of the cellular components, including nucleic acids on the genome 
and in this way to cellular senescence (Harman, 1956; Halliwell, 1991). Hereafter, the theory 
was redefined since mitochondria were identified as both the source and the target of ROS, 
and in particular mtDNA is the main keeper of damage. In fact, the proximity of the mtDNA to 
the ROS source makes it more susceptible to injury, which can be converted to point mutation 
and deletions and the latter can be transmitted and accumulated to daughter molecules 
throughout replication process, changing the hereditary information over time (Shokolenko et 
al., 2014). In this way, the accumulation of mutations in mtDNA may arrive to a critical 
threshold causing adverse effects especially in those mitochondria where components of the 
respiratory chain improperly function or are damaged and need to be replaced (Chistiakov et 
al., 2014). However, inefficient transfer of electrons across the electron transport chain 
generates more ROS, that in turn can damage mitochondria and further decrease the 
efficiency of ETC, constituting a “vicious cycle” that lead to more mitochondrial ROS generation 
and oxidative damage (Ziegler et al., 2014), as well as more mtDNA modifications. Indeed, 
mtDNA shows a high mutation rate, due to its vicinity with ROS source and to the occurrence 
of spontaneous errors generated through DNA replication or unrepaired damage to mtDNA 
that introduces mis-coding lesions (Santoro et al., 2006; Copeland and Longley, 2014). The 
random distribution of mtDNA molecules during cell division can generate two different 
situation: the former is named heteroplasmy and indicates the coexistence of mutated and 
wild-type mtDNA molecules in the same cell, tissue or organ, while the second one is named 
homoplasmy and indicates cells containing only one type of mtDNA molecules, mutated or 
wild-type (Santoro et al., 2006). As suggests by Trifunovic’s experiment on mtDNA mutator 
mice, these random distributed mtDNA mutations are associated with age. In fact, these 
engineered mice accumulated mtDNA mutations during the process of mitochondrial 
biogenesis, due to a defect in the proofreading function of mitochondrial DNA polymerase, 
developing a premature onset of age-related phenotypes, like weight loss, reduces 
subcutaneous fat, alopecia, anemia, reduced fertility, kyphosis, progressive hearing loss, heart 
disease, decreased spontaneous activity and sarcopenia (Trifunovic e al., 2004).  
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Nevertheless, even if it is well known that age-associated mtDNA mutations occur and are 
distributed randomly in the mitochondrial genome, differential pattern of mtDNA point 
mutations accumulation and some differences between in mitotic and post-mitotic tissues 
appear. In particular, base substitutions are the most common type of mtDNA mutations in 
mitotic tissue, while in post-mitotic tissues, large-scale deletions occur more commonly 
(Shokolenko et al., 2014).  
mtDNA deletions refer to mtDNA molecules that have lost large section of the mitochondrial 
genome (Krishnan et al., 2008; fig. 9) and originate as an interplay of large number of base-pair 
direct repeats contained in mtDNA with the asynchronous replication of the heavy and light 
strands (Kovalenko et al., 1998). Recent studies also suggest that mtDNA deletions arise not 
only by defective replication, but also during repair of damaged mtDNA, since during aging, 
oxidative damage leads to generation of double strands breaks that, when are processed, 
generate single-strand regions free to anneal with microhomologous sequences on other 
single-stranded mtDNA or with non coding region. The resulting formation of an intact 
mitochondrial genome carrying a deletion is due to the processes of repair, ligation and 
degradation of the single strands that remain exposed (Cui et al., 2012). Most mtDNA deletions 
share that they are located between the two origins of replication (OH and OL), also known as 
major arc of mtDNA (Krishnan et al., 2008), but a clear pattern of mtDNA deletions show how 
accumulation intervene with age (Kazachkova et al., 2013). Between these, the most studied in 
human is a 4977bp deletion, also named “common deletion”, that generate a mtDNA molecule 
lacking of the genes for NADH dehydrogenase subunits 3, 4, 4L and 5, cytochrome c oxidase 
subunit III and ATP synthase subunits 6 and 8 (Hebert et al., 2010). In 1992, Cortopassi and 
colleagues demonstrated that dissimilar levels of this deletion appeared in different tissues of 
older individuals, and in particular brain stem and brain cortex, heart, psoas and diaphragm 
muscles have higher levels of the common deletion than skin, lung, spleen, kidney and liver. 
They therefore suggested that tissues with elevated oxygen consumption, as muscle and brain 
are, have higher levels of oxidative damage to mtDNA, causing also increased deletion 
frequency (Cortopassi et al., 1992). Later, in 1997, also Zhang and colleagues corroborated this 
study also in animal model, demonstrated that in rats the mtDNA deletions differently 
accumulate in different tissues (Zhang et al., 1997). Therefore, as mtDNA deletions are tissue-
specific, it is likely that mitochondrial dysfunction with different grade of severity are caused 
by different levels of mtDNA deletions (Frahm et al., 2005). 
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Figure 9: Schematic representation of mtDNA deletions in which each line represents a possible deleted region of 
mtDNA (Payne et al., 2011)  
Furthermore, in addition to qualitative changes in mtDNA, also quantitative alterations in 
mtDNA amount (mtDNA copy number) have been associated with mitochondrial disease and 
ageing (Masuyama et al., 2005). Several studies, both in rodents and in humans, were 
conducted but contrasting data emerged about the age-related changes in mtDNA coy number 
(Santoro et al., 2006). Barazzoni and colleagues analyzed mtDNA copy number in rats, 
founding that it was significantly decreased in almost all tissue from old animals even if also 
this reduction showed a tissue-specificity: mtDNA decline was similar in the red and white 
portions of the skeletal muscle gastrocnemius, while it was higher in soleus muscle and highest 
in the liver. Instead, mtDNA copy number did not change with age in rat’s hearts (Barazzoni et 
al., 2000). Also in humans, different tissues show different changes of the amount of mtDNA 
with age. In particular, in human lung there is an age-dependent increase in mtDNA copies 
(Lee et al., 1998), while in blood there is a significant decrease (Bai et al., 2004). A different 
situation appears for skeletal muscle, for which there are any consensus data yet: Pesce 
analyzed mtDNA copy number in vastus lateralis and rectus abdominalis, finding that in both 
the mtDNA content increased about 2-folder in elderly individuals (Pesce et al., 2001). 
However, in 2003 Welle found that in human vastus lateralis, the mtDNA amount diminished 
with age (Welle et al., 2003). Still different data come from the study of Frahm, which, 
analysing mtDNA copy number in five diverse tissues (caudate nucleus, the frontal lobe brain, 
cerebellar cortex, ilipsoas muscle and heart), did not find any significative age-related changes 
(Frahm et al., 2005). These reported discrepancies in mtDNA abundance may be due to the 
different methods utilized to quantify the mtDNA content and also to the region analyzed for 
estimation of mtDNA copy number, especially if this corresponds to the mtDNA region 
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frequently deleted. However, these data also show a marked tissue specificity (Santoro et al., 
2006; Hebert et al., 2010; Kazachkova et al., 2014) that can be attributable to the tissue 
specific need of oxidative metabolism and to its oxidative capacities (Santoro et al., 2006) as 
well as to the developmental stage.  
Therefore, loss of mtDNA copy number control affect human aging (Clay Montier et al., 2009), 
together with respiratory chain deficiency due to high levels of mtDNA rearrangements, like 
clonally expanded deletions (Trifunovic and Larsson, 2008). 
1.2.4 Nuclear-mitochondrial interconnections 
Inside the cells, mitochondria are not self-supporting entities, since the preservation of their 
function are governed by genes present in mitochondrial DNA but also by genes located in 
chromosomal DNA (Taanman JW, 1999; Zhang and Singh, 2014). Moreover nuclear-encoded 
proteins are fundamental for the maintenance and the expression of mtDNA (Trifunovic and 
Larsson, 2008). This is probably due to the fact that during evolution there is a great 
translocation of the original information encoded by mitochondrial genome into the nuclear 
genome, which now coded structural mitochondrial proteins. Thus, nucleus has to be 
constantly informed about the functional status of mitochondria, in order to regulate 
mitochondrial activity, in both physiological and pathological conditions (Santoro et al., 2006; 
Dato et al., 2013). Therefore the cross-talk between nuclear and mitochondrial genome has to 
be intact to ensure normal mitochondrial biogenesis, dynamics, mitophagy, quality of the 
mitochondrial proteins and finally scavenging of ROS (Michel et al., 2012).  
1.2.4.1 Mitochondrial biogenesis 
Mitochondrial biogenesis refers to either the formation of mitochondria during cell cycle, the 
genesis of organelles for normal turnover and the phylogenesis and ontogenesis of 
mitochondria (Attardi and Schatz, 1988; Shepard et al, 1998). As for many processes that 
happening in mitochondria, also mitochondrial biogenesis is dependent of the import of a 
large number of proteins encoded by nuclear genes and then transferred by the translocase of 
the outer mitochondrial membrane (TOMM) complex in the mitochondrial sub-compartments. 
Mutations on these translocases, like for instance TOMM40, lead mice to death in 4-6 weeks 
for abnormal heart, pulmonary vascular congestion and hypertension (Desler and Rasmussen, 
2014). 
Anyway, the formation of new mitochondria depends also by others players, like Pgc-1α, that 
is the main regulator of mitobiogenesis. It is regulated by several external stimuli, such as cold 
exposure, energy deprivation, caloric restriction or physical activity (Michel et al., 2012). In 
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particular physical activity or nutrition stress cause post-translational modification of Pgc-1α 
through the deacetylation mediated by sirtuins (SIRT1 and SIRT3), that are able to activate 
PGC-1α and its mitochondriogenesis pathway (López-Llunch et al., 2008; Gurd, 2011; Johnson 
et al., 2013). In turn, Pgc-1α activates nuclear respiratory factors 1 and 2 (Nrf1/2), which are, 
above all NRF1, potent stimulators of the expression of mitochondrial transcription factor A, 
TFAM (Viña et al., 2009). TFAM, together with DNA polymerase γ (POLγ), twinkle and 
mitochondrial single strand binding protein (mtSSB) are responsible to carry out mtDNA 
replication and repair, through mtDNA helix destabilization and replication, which is an 
essential component of mitochondrial biogenesis (Michel et al., 2012).  
1.2.4.2 Mitochondrial dynamics 
Mitochondria are not isolated organelles, but rather they exist in a dynamic network adapting 
to cellular needs constantly through fusion and fission processes. Moreover, these processes 
are fundamental also to regulate mitochondrial morphology and number (Romanello and 
Sandri, 2010), in an opposing way (Mishra and Chan, 2014). The former generates an extended 
interconnected network, starting from isolated mitochondria which can thus mix their 
contents and redistribute metabolites, proteins and mitochondrial DNA, preventing the 
accumulation of defective or abnormal mitochondria. Instead the latter allows the segregation 
of dysfunctional mitochondria from the network components, resulting in the activation of 
autophagy (Romanello and Sandri, 2010). 
In humans, the key factors of the fusion machinery are GTP-hydrolysing enzymes located 
either in the outer and in the inner membranes: the OMM fusion is driven by mitofusin 1 and 2 
(Mfn1/2), whereas the IMM are fused by dynamin-related protein optic atrophy 1 (OPA1) 
(Zorzano et al., 2010). For the opposite mechanism of fission, dynamin-related protein 1 
(DRP1) and mitochondrial fission 1 (Fis1) are required, leading before to the constriction and 
after to the fission of the mitochondrion (fig. 10; Mishra and Chan, 2014). 
 
Figure 10: Fusion (a) and fission (b) processes in mitochondria (Mishra and Chan, 2014) 
16 
 
1.2.4.3 Mitophagy 
Autophagy is the process by which organelles are surrounded by double membrane that fuses 
with lysosomes, allowing the hydrolytic digestions and recycling (Klionsky, 2007). Mitophagy is 
simply a selective type of autophagy targeted to mitochondria (Okamoto and Kondo-Okamoto, 
2012). Indeed, digestion of the entire organelles by mitophagy allows the control of the 
abundance of mitochondrial population through the right level of turnover (Michel et al., 
2012), but above all mitophagy is the key mechanism of the mitochondrial quality control 
system, which is evolved to avoid cell damage and maintain the overall fitness of the cell 
(Gomes and Scorrano, 2013). Fission is strictly linked to mitophagy, since it generates unequal 
daughter mitochondria, that differ in membrane potential, and in particular, the dissipation of 
the membrane potential lead to proteolytic processing of OPA1, causing the inhibition of 
mitochondrial fusion and ensuring effective mitophagy (Okamoto and Kondo-Okamoto, 2012). 
E3-ubiquitin ligase Parkin (Parkin) and the PTEN-induced putative kinase 1 (PINK1) are the 
main factors that cause the collapse of membrane potential, following by the action of Beclin 
and AMBRA1 (activating molecule in beclin 1-regulated autophagy) that localize on 
endoplasmic reticulum and mitochondrial surface respectively to stimulate autophagy (Michel 
et al., 2012; Okamoto and Kondo-Okamoto, 2012).  
Interestingly, cells lacking mtDNA are autophagic-deficient, but also a controlled degradation 
of the organelle represents a crucial steps for proper mitochondrial and cell function (Michel., 
2012).  
1.2.4.4 Protein Quality Control System 
Mitochondrial proteins, such as the others proteins present inside the cells, have to be kept 
properly folded, while damage or aggregated proteins have to be rapidly degraded by 
proteases (Michel et al., 2012). In particular, oxidized proteins have to be eliminated in order 
to maintain mitochondrial homeostasis (Bulteau el al., 2006). For this reason, inside 
mitochondria there are three known proteases, all of which are able to degrade short-lived, 
misfolded or damaged proteins (Bota et al., 2005). One of these, AAA protease, is localized in 
IMM, whereas Clp and Lon proteases are immersed in the mitochondrial matrix. In particular, 
Lon Protease (LonP) is the most studied, since it is the main protease for degradation of 
oxidized proteins, even if does not recognize a specific consensus peptide sequence (Ngo et al., 
2013).  
LonP is age-modulated, as demonstrated in old rats by Bakala and colleagues. The Lon activity 
in these animals, in fact, was found decreased by 2.5 fold in liver, even if the level of protein in 
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the mitochondrial matrix remained the same, as to indicate Lon inactivation. In heart, instead, 
the activity is similar between young and old rats, but the protein level was 5-fold increased, 
suggesting a sort of compensation for the loss of activity (Bakala et al., 2003).  
1.2.4.5 Super oxide product scavenging 
Inside cells, ROS carry out multiple functions, such as cell migration, proliferation, 
differentiation and they are also essential for signalling cascades. However, when the redox 
equilibrium is lost, ROS abundance causes a state of oxidative stress that is linked also to the 
aging process (Scheurmann et al., 2014). For this reason, during evolution, a variety of defense 
mechanisms have been developed to remove ROS from cells (Trifunovic and Larsson, 2008), 
since they are a well-known cause of oxidative damage, which in turn has long been suggested 
as a possible cause of mtDNA mutations and deletions (Wanagat et al., 2015).  
In mammalian cells sophisticated antioxidant defenses are present in order to scavenge ROS in 
non-toxic forms. These include catalase, glutathione peroxidase and superoxide dismutase, 
SOD (Cui et al., 2012). Superoxide dismutases are responsible to catalyze the conversion of 
superoxide radicals (O2•-) to hydrogen peroxide (H2O2) and O2; inside the cells there are three 
isoforms of SOD that are noticeable by the intercellular localization: SOD1, or CuZn-SOD, is 
present in cytoplasm, SOD2, or MnSOD, is the prevalent mitochondrial isoform, being 
distributed in the mitochondrial matrix, and finally SOD3, or extracellular SOD, that it can be 
found in lymph, synovial fluid, plasma and all the other extracellular fluids (Watanabe et al., 
2014).  
Different sod-null mutant mice were generated in order to understand the role of the different 
SODs: Reaume and colleagues described a shortened lifespan in mice sod1-/- mice (Reaume et 
al., 1996), Li and colleagues studied sod2-/- mice, that showed neonatal lethality (Li et al., 1995) 
and finally Carlsson et al. generated sod3-/- mice which, conversely from the others, exhibited a 
shorter survival time under hyperoxic condition, with no apparent abnormalities until late in 
life (Carlsson et al., 1995).  
 
1.3 Telomeres 
1.3.1 Telomeres and aging 
Telomeres are long sequences of non-coding DNA, located at the end of chromosomes, where 
the specific TTAGGG hexanucleotide sequence is repeated thousands time in tandem and is 
associated with protein complexes. Shelterin is the name of the specialized multi-protein 
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complex, composed by six proteins: TRF1 and TRF2, binding telomeric double strand DNA, 
RAP1 that interacts with TRF2, TIN2 and TPP1, which are linker proteins that stabilize and hold 
the complex together and POT1, that instead binds telomeric single strand DNA. In fact, 
telomeres contain a region of double-stranded (ds) and a region of single-stranded (ss) DNA, 
that is an extension at the 3’ end of the G-rich strand and consists in about 100 nucleotides. It 
can form a telomere-loop (t-loop) structure, in order to mask the chromosomal ends by 
strand-invading into the ds DNA thus forming a displacement loop (D-loop) (Sahin and 
DePinho, 2012). This peculiar structure allows performing two protective functions: telomere 
prevent chromosomal end-end fusion and non reciprocal translocation (Hoare et al., 2010).  
Indeed, at each cellular division a telomeric fragment of 50-200bp is lost, causing progressive 
shortening of telomeres that, in fibroblast, is related to progressive loss of the proliferation 
capacity after a limited number of cell divisions, a phenomenon called by Hayflick limit or 
cellular replicative senescence (Hayflick and Moorhead, 1961).  
Senescence is now known to be triggered by telomeres shortening or disruption, but it is 
largely heterogeneous, probably because several factors participate, such as telomere 
structure and composition, telomerase availability and activation state, interplay between 
proteins, telomerase and DNA replication machinery (Stewart et al., 2012). Also environmental 
factors like stress, pathologies and ROS can increase telomere shortening by increasing 
telomeric DNA damage and telomere shortening rate (Saretzki and von Zglinicki, 2002). 
However, telomere length is regulated by telomerase, i.e. a reverse transcriptase consisting of 
a complex of several proteins and RNA template (Cong et al., 2002), that increases telomere 
length adding TTAGGG repeats, in order to maintain the telomeric length in embryonic cells, in 
adult stem cells and finally in cancer cells (Hoare et al., 2010). Conversely, in most somatic cells 
telomerase is suppressed within few weeks after birth (Oeseburg et al., 2010). Moreover, it 
was seen that in some human premature diseases telomerase complex is mutated, resulting in 
decreased telomerase stability and shorter telomeres (Mitchell et al., 1999), proving a 
plausible involvement in aging process.  
1.3.2 Telomere and mitochondria, a connection in aging  
Since mitochondria are the most important source of ROS in the cells, a possible role of 
mitochondria and oxidative stress in telomere-driven replicative senescence has been 
proposed. Knowing that ROS production and mitochondrial dysfunction are involved in aging 
and that mitochondrial dysfunction induces a retrograde response to signal the disruption of 
the ETC to the nucleus, it is possible that nucleus implement an adaption response. Likely, this 
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retrograde signalling of adaption response corresponds to the up-regulation of mitochondrial 
biogenesis induced by PGC-1α and PPARγ and increases mitochondrial uncoupling, causing a 
reduction in ROS production by the mitochondria, with less oxidative stress impacting on 
telomeres (Passos et al., 2007).  
Supporting the connection between telomeres and mitochondria during aging there is the fact 
that chronic or mild long lasting oxidative stress causes exportation of telomerase from the 
nucleus to the mitochondria, avoiding its activity on telomeres. However, it has been shown 
that the catalytic subunit of telomerase (TERT) may have a telomere-independent function in 
mitochondria, carrying out the protection of mitochondria and mtDNA from ROS-induced 
damage as a result of improved mitochondrial function, decreased ROS production, increased 
mitochondrial coupling and suppressed retrograde response (Ahmed et al., 2008). 
Basing on the fact that telomere maintenance is controlled also by some proteins involved in 
the repair pathways, it is clear that active genome maintenance and repair systems are 
fundamental to avoid premature aging. Thus, a constitutive activation of repair pathways with 
sustained p53 induction could be due to shortened of disrupted telomeres, as signal of DNA 
damages. In turn, p53 activation can lead to cell growth arrest, stimulation of repair, apoptosis 
or senescence pathways depending on its degree of activation, in addition to mitochondrial 
changes, due to its binding with the promoter of the mitochondrial transcriptional co-
activators family of PGC-1α, master regulators of mitochondrial biogenesis, as shown in figure 
11 (von Zglinicki et al., 2001; Sahin and De Pinho, 2012;). 
 
Figure 11: Telomeres-p53-PGC aging pathway (Sahin and De Pinho, 2012).  
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2 Aim of the thesis 
Aging is characterized by an increasing propensity to degenerative diseases and death due to 
the progressive decline in the functional maintenance of tissue homeostasis (Hayflick, 1998), 
caused by the accumulation of unrepaired and deleterious changes of molecules and cells. 
Thus, in order to compensate and neutralize the adverse effects of such damages, each tissue 
acts out a series of adaptive mechanisms resulting in the tissue-specificity of the aging process 
(Meissner et al., 2006; Ostan et al., 2008). 
However it is well known that age-related declines in mitochondrial function underlie several 
of those biological changes that cause an incremented vulnerability to multiple disease states, 
functional and cognitive decline and, at the end, mortality (Ashar et al., 2014). Mitochondrial 
dysfunction includes decreased oxidative capacity and increased oxidative damage to 
biomolecules (DNA, proteins and lipids) due to the excessive production of reactive oxygen 
species, which are highly toxic (Chistiakov et al., 2014). In particular, ROS can damage 
mitochondrial component like mitochondrial DNA (mtDNA), causing mtDNA point mutations, 
varying its copy number or inducing mtDNA deletion. Thus, mtDNA rearrangements, intended 
as mtDNA copy number, deletion level and integrity, are likely to play an important role in the 
aging process. Several studies investigate mtDNA copy number or mtDNA deletion in different 
tissue from either human and animal models but data on mtDNA rearrangements are still 
controversial.   
Thus, in order to understand the involvement of mtDNA rearrangements during human aging, 
the primary aim of this thesis is the analysis of mtDNA copy number, deletion level and 
integrity, in human biopsies from liver, vastus lateralis skeletal muscle from healthy subjects 
and patients with limited mobility of lower limbs (LMLL) undergone hip replacement surgery, 
and adipose tissue. The biopsies were recruited in the framework of the project MIUR-PRIN 
2008, for what concern liver, whereas all muscle and adipose tissue biopsies were recruited in 
the framework of the European project MYOAGE (Understanding and Combating age related 
muscle weakness; FP7-223576; 2008-2012), and all of them are from subjects at different ages.  
Moreover, the telomere length was also investigated, considering its possible relationship with 
mitochondrial function (Sahin et al., 2011) and its role as marker of cellular aging.  
To further characterise the involvement of mtDNA rearrangements in the aging of human liver, 
skeletal muscle and adipose tissue, the expression of nuclear genes related to mitochondrial 
biogenesis (pgc-1α, polɣ, nrf1, tfam, twinkle, sirt1, sirt3, tomm40 and ppard), mitochondrial 
dynamics, i.e. fusion and fission processes (mfn2, fis1 and opa1), mitophagy (ambra1, beclin, 
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pink1, parkin, atg16l and pik3cd), mitochondrial protein quality control system (lonp), 
production of ROS (nos3), protection from ROS (sod1 and sod2) and hypoxia (hif-1α) were also 
evaluated in the same samples. 
Finally, a comparison among the considered tissues was realized, in order to understand the 
tissue specificity of mtDNA rearrangements and to extend the comprehensive and age-
independent vision of tissue-related variability in mtDNA rearrangements and of the nuclear 
genes expression involved in mitochondrial pathways, which is still poor of evidences. 
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3 Materials and methods 
3.1 Tissues samples 
For the present work, biopsies from three different human tissues have been collected. 
For human liver, 82 biopsies have been obtained from organ donors at different ages (13-84 
years) in collaboration with the Unit of Surgery of liver and multi-organ transplants of the S. 
Orsola-Malpighi Hospital in Bologna, in the framework of the project MIUR-PRIN 2008 
coordinated by Dr. Gianluca Grazi (Transplantation Unit) and Dr. Miriam Capri (Lab of 
Immunology of Prof. Franceschi). The biopsies have been recovered during the explants of the 
liver, which were performed at beating heart. 
For skeletal muscle, biopsies of vastus lateralis were taken from two group of subjects 
recruited in the framework of the European Project MYOAGE. The former was the patients 
group, i.e. 50 biopsies from subjects with lower limb mobility impairment (LLMI) who 
underwent hip replacement surgery, recruited in Bologna, Italy (Prof. Ermanno Martucci, 
Istituto Ortopedico Rizzoli, Bologna). The latter enclosed 109 biopsies from healthy subjects of 
two different age groups, subjects under 40 years and subjects that are more than 65 years 
old, coming from Tartu, Estonia (Prof Enn Seppet, Centre of Molecular and Clinical Medicine, 
University of Tartu) and Leiden, the Netherlands (Prof. Andrea Mayer, Department of 
Gerontology and Geriatrics, Leiden University).  
From LLMI patients were also picked up 20 biopsies of adipose tissue in order to obtain two 
different tissues from the same subjects. For this reason, the range of age of adipose tissue is 
the same of LLMI patients group (24-89 years).  
Table 1 shows the number of samples studied in this thesis grouped by tissue, age and gender. 
 Liver LLMI muscle Adipose Tissue Healthy muscle 
Age Group 
(age range) 
Gender Total Gender Total Gender Total Age Group 
(age range) 
Gender Total 
 M F  M F  M F   M F  
1: ≤30 10 5 15 10 5 15 2 1 3 1: ≤40 15 21 36 
2: 31-50 10 4 14 7 4 11 3 1 4 2: ≥65 38 35 73 
3: 51-70 11 15 26 5 7 12 2 3 5     
4: ≥71 14 13 27 6 6 12 4 4 8     
Table 1: Biopsy samples of different tissue divided by age and gender. 
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3.2 Nucleic acid isolation and purification 
3.2.1 DNA isolation  
3.2.1.1 Liver and skeletal muscle biopsies 
Quick-gDNA™ MiniPrep kit from Zymoresearch (USA) was used to isolate total DNA from liver 
and vastus lateralis muscle biopsies, since it allowed the isolation of total DNA from various 
biological sample sources, including different solid tissues, as in this case. 
To obtain total DNA is not require the use of organic denaturants or Proteinase K digestion, 
but just columns with high DNA affinity. Following the provided data sheet: 
1. Homogenize about 25mg of frozen biopsy in 500μl of Genomic Lysis Buffer by an 
automatic homogenizator 
2. Centrifuge the lysate at 10000 x g for 5 minutes  
3. Transfer the supernatant to a Zymo-Spin™ Column in a Collection Tube, without 
disturb the pellet debris 
4. Centrifuge at top speed for one minute and discard the Collection Tube with the flow 
trough and transfer the Zymo-Spin™ Column to a new Collection Tube 
5. Add 200μl of DNA Pre-Wash Buffer to the spin column and centrifuge at 10000 x g for 
one minute 
6. Discard the flow trough, add 500μl of g-DNA Wash Buffer to the spin column and 
centrifuge at 10000 x g for one minute 
7. Transfer the Zymo-Spin™ Column in a new and clean eppendorf tube and add 70μl of 
Elution Buffer  
8. Incubate for 5 minutes at room temperature  
9. Centrifuge at 10000 x g for 30 seconds to elute DNA 
Purified DNA is suitable for many experiments, like quantitative Real Time PCR, but before its 
use, all samples were quantified by Nanodrop spectrophotometer (see paragraph 3.2.4) and 
normalized to a working concentration of 0,4ng/μl. 
3.2.1.2 Adipose tissue biopsies 
To isolate total DNA from adipose tissue biopsies ZR Genomic DNA™ –Tissue MiniPrep kit from 
Zymoresearch (USA) was utilized since it allowed the isolation of total DNA from specific solid 
tissues, as adipose tissue. 
Following the provided data sheet: 
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1. Put a sample of about 25mg of frozen biopsy in a microcentrifuge tube and add, 
mixing, 95μl of H2O, 95μl of 2X Digestion Buffer and 10μl of Proteinase K. Incubate the 
eppendorf at 55°C for 3hours 
2. Add 700μl of Genomic Lysis Buffer to the tube and vortex 
3. Centrifuge at 10000 x g for 1 minute to see insoluble debris 
4. Without disturb the pellet, transfer the supernatant to a Zymo-Spin™ Column in a 
Collection Tube and centrifuge at 10000 x g for 1 minute 
5. Change the Collection Tube and add 200μl of DNA Pre-Wash Buffer to the spin column. 
Centrifuge at 10000 x g for one minute 
6. Discard the flow trough, add 400μl of g-DNA Wash Buffer to the spin column and 
centrifuge at 10000 x g for one minute 
7. Transfer the Zymo-Spin™ Column in a new and clean eppendorf tube and add 70μl of 
water and incubate for 5 minutes at room temperature  
8. Centrifuge at 10000 x g for 30 seconds to elute DNA 
After purification, all DNA samples were quantified by Nanodrop spectrophotometer (see 
paragraph 3.2.4) and normalized to the working concentration of 0,4ng/μl. 
3.2.2 RNA isolation 
RNA was extracted by mirVana Isolation Kit (Life Technologies, California, USA), from about 
25mg of frozen biopsies from each tissue.  
The whole procedure was performed on ice, and the following protocol has been used: 
1. Mechanically homogenize the biopsies in 10 volumes per tissue mass of lysis buffer 
(Lysis\Binding Buffer)  
2. Add 1/10 volume of miRNA Homogenate Additive to the homogenate and incubate for 
10minutes  
3. Add a volume of acid-phenol:chloroform equal to the initial volume of lysate and mix 
by vortex for 60 seconds 
4. Centrifuge at 10000 x g for 10 minutes to separate aqueous and organic phase 
5. Transfer carefully the aqueous upper phase, containing the RNA, in a new eppendorf 
and add 1.25 volumes of room temperature 100% ethanol, mixing with pipette 
6. Transfer up to 700 μl of solution to a spin-column (Filter Catridge with Collection Tube) 
and centrifuge at 10000 x g for 30 seconds. Discard the flow through and repeat until 
all solution pass to the filter 
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7. Add 700 μl of Wash Solution 1 and centrifuge at 10000 x g for 30 seconds, discarding 
the flow through  
8. Wash two time the filter through adding 500 μl of Wash Solution 2/3, and centrifuging 
at 10000 x g for 30 seconds 
9.  Transfer the filter to a new eppendorf and add 70 µl of pre-heated 95°C RNase-free 
sterile H2O. Centrifuge at 10000 x g for 30 seconds to elute RNA 
Isolated RNA was tested with electrophoresis on 1% agarose gel to evaluate the quality and 
integrity. Each sample was prepared with 3 µl extracted RNA, 2 µl H2O and 1 µl Bromophenol 
6X, loaded on the gel and run at 60-80 V for 30-45 minutes, monitoring voltage and run time to 
avoid excessive heating and RNA degradation. A positive control RNA has been also loaded on 
the gel. Extracted RNA was stored at -80°C. 
3.2.3 RNA treatment with DNAse 
To eliminate possible DNA traces, RNA extracted with mirVANA Isolation Kit was treated with 
DNase of Turbo DNA-free kit (Life Technologies, California, USA). Following the company 
indications, 2 µl of Turbo DNase Buffer and 1 µl of Turbo DNaseI enzyme were added to 17 µl 
of RNA and incubated at 55°C for 25 minutes. After this incubation time, 2 µl of DNase 
Inactivation Reagent were added to the mixture that was incubated for 5 minutes at room 
temperature and then centrifuged at 10000 x g for 90 seconds. Later than centrifugation, the 
supernatant was recovered avoiding removal or touching of the pellet with pipette tip and 3 µl 
of treated RNA were transferred in a new eppendorf to quantify them by Nanodrop 
spectrophotometer (see paragraph 3.2.4). 
3.2.4 Nucleic acid quantification 
NanoDrop 1000 spectrophomometer (Thermo Scientific, Wilmington, USA) was used to 
quantify isolated DNA and DNase treated RNA in order to later normalize samples in the 
working solutions.  
Measurements for both DNA and RNA were expressed as ng/μl and taken in triplicate, utilizing 
each time 1 µl of sample. The mean value was used as final concentration. Also other two 
parameters (260/280 and 260/230 ratio) were taken into account to assess samples purity and 
identify potential contaminations. In particular, for the 260/280 ratio values should be around 
1.8 for pure DNA and around 2.0 for pure RNA, while for the ratio 260/230 around 2.0-2.2. 
Lower values may indicate presence of contaminants and residues of reagent used in the 
extraction protocol (for example phenol). 
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3.3 cDNA synthesis 
SuperScript® III First Strand Synthesis System for RT-PCR (Life Technologies, California, USA) 
was used to convert DNase treated RNA in cDNA.  
Following the provided protocol, the quantified RNA was used to start with 750ng, 250 ng and 
150 ng of RNA for liver, muscle and adipose tissue respectively for a maximum of 12,5 µl. To 
this first solution of RNA and water, 0,5 µl of Random Primer 3 µg/µl and 1 µl of dNTPs 2.5 mM 
were added and incubated for 5 minutes at 65°C on ice for 2 minutes. Then, before continuing 
the RT-PCR program, 4 µl of Buffer FS 5X, 1 µl of DTT 0.1M and 0,5 µl of SuperScript III 200 U/ 
µl were added to each starting solution.  
All the reagents used for the cDNA synthesis reaction and the overall RT-PCR program are 
summarized in the tables 2 and 3: 
Reagent Volume Step 
DNAseI treated RNA 750/250/150 ng  
Random primer 3 µg/ µl 0.5 µl 
Addition 1 
dNTPs 2.5 mM 1 µl 
Buffer FS 5X 4 µl 
Addition 2 DTT 0.1 M 0.5 µl 
SuperScript III 200 U/ µl 0.5 µl 
Table 2: RT-PCR reagents for cDNA synthesis. 
Steps 
5’ at 65°C 
2’ on ice 
Addition 2 
5’ at 25°C 
50’ at 50°C 
15’ at 72°C 
Table 3: RT-PCR program for cDNA synthesis. 
cDNA was then diluted 1 to 10 to use it for qPCR assays and then stored at -80°C. 
 
3.4 Quantitative Real Time PCR SYBR® Green assay  
Quantitative Real Time polymerase chain reaction (qPCR) assay allows the simultaneous 
amplification and quantification of target nucleic acid after every reaction cycle, detecting the 
amplification product through the use of a fluorophore. In this case, the used fluorophore is 
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SYBR® Green I, enclosed in the two utilized master mixes, MesaGreen qPCR MasterMix for 
SYBR® Assay No Rox (Eurogentec, Belgium) and iTaq™ Universal SYBR® Green Supermix (Bio-
Rad, USA). Both master mixes contain also the other necessary components for the 
amplification reaction, like dNTPs, MgCl2, and stabilizers but they differ for the polymerase 
enzyme (MeteorTaq DNA polymerase and antibody-mediated hot-start iTaq DNA polymerase, 
respectively) and thus for the thermal profile that has to be used. The fluorophore is important 
because it binds aspecifically double-strand DNA (dsDNA) and the complex fluorophore-DNA 
absorbs blue light at wavelength λmax = 494 nm and emits green light with λmax = 520 nm, in 
order to monitor the reaction progression. The melting curve analysis, instead, consent to 
evaluate the specificity of the amplification, which relies mainly on the primers, since it is built 
at the end of the amplification reaction by a gradual and regular increase in temperature that 
gradually denature the dsDNA. When the dsDNA is denaturated, the intensity of the 
fluorescence dramatically decreases, as shows the melting curve graph. The trend illustrates a 
pick which represents the temperature at which the 50% of DNA duplex are disrupted (melting 
temperature, Tm). The Tm is specific for each amplicon. Real time PCR was performed on a 
Rotor-Gene Q 6000 (Qiagen, USA) thermalcycler, that has a Rotor Gene Q Series Software 
being able to analyze qPCR data with a comparative method, since it compare the Ct values of 
the samples of interest with that of a sample used as calibrator which will be run with all 
samples, without using a standard curve as a reference. The Ct values represent the number of 
cycle required for the fluorescent signal to cross the threshold and is inversely proportional to 
the amount of target nucleic acid in the sample. The quantification of the samples were then 
obtained with the delta delta Ct (ΔΔCt) method (Pfaffl, 2001), since the final value is gained 
from the subtraction of the delta Ct of the gene of interest and the delta Ct of the gene used as 
reference.  
This method has been used to assess in each tissue: 
 mtDNA rearrangements (mtDNA copy number, deletion level and integrity) on 
extracted DNA  
 telomere length on extracted DNA  
 gene expression on cDNA synthetised from isolated RNA  
The details of each assay are described below. 
3.4.1 mtDNA rearrangements analysis 
As written above, real time qPCR SYBR® Green assay has been used to determine copy 
number, deletion level and integrity of mtDNA. 
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To quantify mtDNA copy number a primers pair to amplify the mitochondrial gene nd1, located 
in a portion of the mtDNA rarely deleted and a primers pair to amplify a nuclear gene, β-actin, 
which is necessary to normalize mtDNA were chosen.  
Instead to quantify mtDNA deletion level, primers for the gene nd4, which is located in the 
major arch of the mtDNA where deletion frequently occurs, where used in combination with 
those for nd1.  
The ratio between mtDNA deletion level and mtDNA copy number represents the mtDNA 
integrity, intended as the number of deleted molecules on the total number of mtDNA 
molecules. 
The sequences of utilized primers are described in table 4: 
Gene Primers sequence Product size 
ND1 
FOR: CCCTAAAACCCGCCACATCT 
REV: GAGCGATGGTGAGAGCTAAGGT 
94 
ND4 
CCATTCTCCTCCTATCCCTCAAC 
REV: CACAATCTGATGTTTTGGTTAAACTATATTT 
98 
ACTB 
FOR: ACCCACACTGTGCCCATCTAC 
REV: TCGGTGAGGATCTTCATGAGGTA 
107 
Table 4: Pairs of primers for mtDNA deletion level and copy number. 
The qPCR assays were conducted on Rotor gene Q 6000 system (Qiagen, USA). The assays for 
nd1, nd4 and actin were run together on the same samples in different tube in duplicate. To 
obtain compelling results and to perform significant statistical analysis, qPCR reaction was run 
three times. 
Each mix was prepared by following the directions supplied with the Eurogentec MasterMix 
(Eurogentec, Belgium) protocol in a final reaction volume of 10μl, as described in table 5. In 
table 6, instead, is described the thermal profile used for qPCR assays, as indicate in the 
protocol provided with MasterMix by Eurogentec.  
Component Volume per 1 reaction 
Mesa Green qPCR MasterMix  
for SYBR Assay No Rox (Eurogentec) (2X) 
5 µl 
Primer forward (10 µM) 0.15 µl 
Primer revers (10 µM) 0.15 µl 
DNA (0.4 ng/µl) 3 µl 
H2O 1.7 µl 
Final volume 10 µl 
Table 5: Reagents mix used for the real time assays. 
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Condition Cycles Step 
95°C for 5 min  Initialization 
95°C for 15 sec 
40 cycles 
Template denaturation 
60°C for 60 sec Primers annealing 
72°C for 20 sec DNA synthesis 
From 55°C to 99°C  Melt 
Table 6: Thermal profile of qPCR assays for Eurogentec MasterMix. 
3.4.2 Telomere length analysis 
To assess telomere length with a relative quantification method a pool of six different DNAs 
from young subjects was used as calibrator sample in qPCR assays. The primers chosen for 
telomere and for the reference gene are taken from Cawthon et al., 2002 and are listed in 
table 7. 36B4 is the reference gene and encodes for the acidic ribosomal phosphoprotein P0. 
The ratio between the amounts of telomeres and 36B4 was used to calculate the telomere 
length. 
Primers Sequences 
Telomere 
For: 5’-GGTTTT-TGAGGGTGAGGGTGAGGGTGAGGGTGAGGGT-3’ 
Rev: 3’-TCCCGACTATCCCTATCCCTATCCCTATCCCTATCCCTA-5’ 
36B4 
D: 5’-CCCATTCTATCATCAACGGGTACAA-3’ 
U: 5’- CAGCAAGTGGGAAGGTGTAATCC-3’ 
Table 7: Primers pair for telomere and 36B4. 
As previous, the reaction and the thermal profile were set up following the protocol provided 
with MesaGreen qPCR MasterMix as shown in table 8 and 9. 
Reagent Volume per 1 reaction 
Mesa Green qPCR MasterMix  
for SYBR Assay No Rox (Eurogentec) (2X) 
5 µl 
Primer forward (10 µM) 0.15 µl 
Primer revers (10 µM) 0.15 µl 
DNA (0.4 ng/µl) 3 µl 
H2O 1.7 µl 
Finale volume 10 µl 
Table 8: Mix used during the assay to determine the telomere length. 
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Condition Cycles Step 
95°C for 5 min  Initialization/activation 
95°C for 15 sec 
40 cycles 
Template denaturation 
60°C for 60 sec Primers annealing 
72°C for 20 sec DNA synthesis 
From 65°C to 90°C  Melt 
Table 9: Thermal profile of the qPCR assay. 
To obtain compelling results and to perform significant statistical analysis, qPCR reaction was 
performed in duplicate and each run was repeated three times. Telomere length was 
calculated as the ratio between the amounts of telomeres with reference to 36B4 gene. 
3.4.3 Gene expression analysis 
Purified RNA converted in cDNA was used in qPCR to evaluate the gene expression level of 
different nuclear genes, involved in several mitochondrial pathways. 
For mitobiogenesis, the analyzed genes are pgc-1α, polɣ, nrf1, tfam, twinkle, sirt1, sirt3, 
tomm40 and ppard. In the table below are reported the primers used. 
Gene Primers Product size 
pgc-1α 
FOR: AGACACCGCACGCACCGAAA 
REV: GCCGACGGCTGTAGGGCGAT 
70 bp 
polɣ 
FOR: TGTCAACCAGAACTGGGAGCGTTA 
REV: TGGCCAGATCCATCAACGACTTCT 
95 bp 
nrf1 
FOR: TGTAGAACTTCATGGAGGAACAC 
REV: CACATGGACCTGCTGCACTT 
98 bp 
tfam 
FOR: GAAGCATGTGGGGCGTGCTGA 
REV: GGGAGCGCAGTCGACTTCCAC 
81 bp 
twinkle 
FOR: GTGGGCCAACAGGCAGTGGAA 
REV:CCGCCCCTCGGCAAACTGTG 
147 bp 
sirt1 
FOR: TCCTGGACAATTCCAGCCATCTCT 
REV: TTCCAGCGTGTCTATGTTCTGGGT 
103 bp 
sirt3 
FOR: GCCGCACTTCTAGCATGTTG 
REV: CCTGCAGTCCCTTTGAGGAG 
107 bp 
tomm40 
FOR: CCGGAATTGAGGGGCACGCA 
REV: TGGAGGATGGGGACGCCAGG 
92 bp 
ppard 
FOR: AGCTGGAGTACGAGAAGTGTGAGC 
REV: GATAGCGTTGTGTGACATGCCCAG 
116 bp 
Table 10: Primers pair for genes involved in mitobiogenesis. 
As shown in table 11, for the processes of fusion and fission, the genes considered are mfn2 
for fusion and fis1 and opa1, for fission. 
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Gene Primers Product size 
mfn2 
FOR: GACCAAGTTTGAGCAGGCACACG 
REV: TTCAGCCATTTCCTCGCAGTAA 
121 bp 
fis1 
FOR: CCAAGAGCACGCAGTTTGAG 
REV: GAGCAGCACGATGCCTTTAC 
83 bp 
opa1 
FOR: GCTGCCCGCCTAGAAAGGGTG 
REV: CCCTCCCAATGGCGCATGGA 
97 bp 
Table 11: Primers pair for genes involved in fusion and fission processes. 
From literature is known that ambra1, beclin, pink1, parkin, atg16l and pik3cd are involved in 
mitophagy process, thus these are the genes chosen to evaluate this pathway. 
Gene Primers Product size 
ambra 
FOR: CAGGCCTCGTCAACGCAGCA 
REV: CGGCGGGTAGGACCCAGACT 
119 bp 
beclin 
FOR: ACAGTGCCTCCGCGGTAGACC 
REV: ACGAAGCTCACCTGCATGGTGC 
116 bp 
pink1 
FOR: TGGGGAGTATGGAGCAGTCA 
REV: CGGAGAACCCGGATGATGTT 
87 bp 
parkin 
FOR: AGCCGGGAAAACTCAGGGTA 
REV: TGGCATTCACCACTCATCCG 
118 bp 
atg16l 
FOR: TGCCGGCATTCCCGCTTCTG 
REV: GGCACCTCAGCGCCACCAAT 
85 bp 
pik3cd 
FOR: ACCAAGGAGGAGAATCAGAGCGTT 
FOR: ACCAAGGAGGAGAATCAGAGCGTT 
101 bp 
Table 12: Primers pair for genes involved in mitophagy. 
Also the expression level of the genes for superoxide dismutases 1 and 2 (sod1 and sod2) were 
considered, together with the expression level of nos3, which is, instead, involved in the 
production of reactive oxygen species. 
Gene Primers Product size 
sod1 
FOR: GGAGACGGGGTGCTGGTTTGC 
REV: TAACTCGCTAGGCCACGCCG 
97 bp 
sod2 
FOR: TGGGGACTTGTAGGGATGCCTTT 
REV: AGAAAGCCGAGTGTTTCCCTTGG 
123 bp 
nos3 
FOR: GACGTGGTGTCCCTCGAACACG 
REV: CTCCATCAGGGCAGCTGCAAAGC 
108 bp 
Table 13: Primers pair for genes involved in protection from and production of ROS. 
Finally, the expression level of lonp and hif-1α were assessed as indicative of the protein 
system quality control and the level of hypoxia, respectively. 
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Gene Primers Product size 
lonp 
FOR: AAACGCATCCTGGAGTTCATTGCC 
REV: ATGGAGCGAGCAATGCTGGTCTTA 
113 bp 
hif-1α 
FOR: ACCTATGACCTGCTTGGTGC 
REV: GGCTGTGTCGACTGAGGAAA 
98 bp 
Table 14: Primers pair for genes encoding LONP and HIF1α. 
The gene chosen as house-keeping was β-actin. Each cDNA sample was run in duplicate and 
each run was performed twice. The reaction and the thermal profile were set up as indicated 
in the protocol: 
Component Volume per 1 reaction 
iTaq™ Universal SYBR® Green Supermix (Bio-Rad) (2X) 5 µl 
Primer forward (10 µM) 0.15 µl 
Primer revers (10 µM) 0.15 µl 
cDNA dil. 1:10 2 µl 
H2O 2.7 µl 
Final volume 10 µl 
Table 15: Mix used during the assay to evaluate genes expression levels. 
Condition Cycles Step 
95°C for 30 sec  Polymerase Activation 
95°C for 5 sec 
40 cycles 
Denaturation 
60°C for 30 sec 
Annealing/ Extension and 
Plate Read at 60°C 
From 65°C to 90°C  Melt-Curve Analysis 
Table 16: Thermal profile of the qPCR assay with iTaq™ Universal SYBR® Green Supermix (Bio-Rad) (2X). 
 
3.5 Statistical Analysis 
All the analyses were performed by the software STATA v.9.0. (Stata Corp. Texas, USA) and p-
values < 0.05 were considered as significant. Values, which deviate from the average more 
than three times the variance, were considered outliers and excluded from the analysis. 
Regression analysis has been used to correlate age, as a continuous variable, with the levels of, 
mtDNA relative copy number, mtDNA relative deletion level, mtDNA integrity, and telomere 
length as well as the expression levels of the considered genes.  
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Data were analyzed by Analysis of Variance (ANOVA) test when age was considered as a 
discrete variable (age-group) and to compare mtDNA rearrangements and gene expression 
level among the different tissues. 
Shapiro-Wilk, Shapiro-Francia and Skewness/Kurtosis tests were employed to verify if variables 
follow a normal distribution and are homoscedastic (that is with finite variance). When these 
criteria were not satisfied, Mann-Whitney or Kruskal-Wallis tests were applied to compare two 
groups or four groups of variables, respectively. Bonferroni’s correction was applied for 
multiple comparisons and the level of significance was set at p<0,0083. 
  
34 
 
4 Results 
In order to understand the role of mtDNA rearrangements in the aging of human liver, skeletal 
muscle and adipose tissue, mtDNA relative deletion level, copy number and mtDNA integrity 
were evaluated using DNA isolated from biopsies of these different tissues, as reported in 
table 1 of materials and methods. In each tissue, the above mentioned variables were analyzed 
in relation to age and then in females and males separately in order to observe any possible 
gender differences. 
Telomere length was also measured on the same DNA samples to assess its association with 
age, gender and mtDNA rearrangements. 
Furthermore, the expression level of nuclear genes involved in several mitochondrial 
pathways, responsible for impacting on mtDNA rearrangements, was evaluated: 
 pgc-1α, polɣ, nrf1, tfam, twinkle, sirt1, sirt3, tomm40, ppard for mitobiogenesis 
 mfn2, fis1 and opa1 for fusion and fission processes 
 ambra1, beclin, pink1, parkin, atg16l and pik3cd for mitophagy  
 nos3 for production of ROS 
 sod1 and sod2 for protection from ROS 
 lonp for the protein quality control system 
 hif-1α for hypoxia 
All these genes were evaluated in relation to age, gender, mtDNA rearrangements and 
telomere length to understand which of these genes regulating mitochondrial function is 
expressed or not during human aging process. 
Data are presented in four sections: one for liver, one for skeletal muscle, one for adipose 
tissue and one comparing the results of the three different tissues in order to unravel the 
tissue-specific role of mtDNA rearrangements during aging. 
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4.1 Human Liver 
4.1.1 mtDNA copy number 
mtDNA copy number was quantified by measuring the amount of mitochondrial gene nd1 
located in the rarely deleted mtDNA portion compared to the reference gene β–actin, that is 
nuclear. 
mtDNA copy number was found to significantly increase with age in the total number of 
subjects (p=0.0422, R2=0.0506; figure 12a); a gender difference also appeared when analysis 
was conducted separately: in females there was any significative difference (p=0.4044, 
R2=0.1392), while in males a significant increase in mtDNA copy number with age was found 
(p=0.0318, R2=0.3242; figures 12b and 12c). 
 
Figure 12: Regression analysis of mtDNA copy number as a function of age was performed in 82 DNA samples 
from liver biopsies. a.) In the total number of samples (N=82), mtDNA copy number significantly increases with 
age (p=0.0422; R2=0.0506). b.) In females (N=38) mtDNA copy number does not change significantly with age 
(p=0.4044; R2=0.1392 ). c.) In males (N=44) mtDNA copy number significantly increases with age (p=0.0318; 
R2=0.3242). 
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4.1.2 mtDNA deletion level 
mtDNA deletion level was analyzed with qPCR, quantifying the amount of the mitochondrial 
gene nd1, located in the mtDNA arch rarely deleted, compared with the mitochondrial gene 
nd4, located in the major arch of mtDNA frequently deleted.  
As shown in fig. 13a, in the total of samples, mtDNA deletion level did not significantly change 
with age (p=0.3802, R2=0.0096). Even when regression analysis was performed on female and 
male subjects separately (figures 13b and 13c), no gender difference emerged (p=0.1926 and 
R2=0.0467, p=0.9477 and R2=0.0001, respectively ).  
 
Figure 13: Regression analysis of mtDNA deletion level as a function of age was performed in 82 DNA samples 
from liver biopsies. a.) In the total number of samples (N=82), mtDNA deletion level does not change significantly 
with age (p=0.3802; R2=0.0096). b.) In females (N=38) mtDNA deletion level does not change significantly with 
age (p=0.1926; R2=0.0467). c.) In males (N=44) mtDNA deletion level does not change significantly with age 
(p=0.9477; R2=0.0001). 
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4.1.3 mtDNA integrity 
Deeper analyzing the relationship between mtDNA deletion level and copy number, a strong 
correlation was found between these two parameters (p=0.0000, R2=0.1907), as shown in 
figure 14a. This strong correlation was maintained also when samples were analyzed by 
gender: both females and males displayed a significant decrease of mtDNA deletion level as 
copy number increase (female: p=0.0211,R2=0.1391, fig. 14b; males: p=0.0006, R2=0.2464, fig. 
14c). 
 
Figure 14: Regression analysis of mtDNA deletion level as a function of mtDNA copy number in 80 DNA samples 
from liver biopsies. a.) In the total number of samples (N=80), mtDNA deletion level significantly decreases with 
the increase of mtDNA copy number (p=0.0000; R2=0.1907). b.) In females (N=37) mtDNA deletion level 
significantly decreases with the increase of mtDNA copy number (p=0.0211; R2=0.1391). c.) In males (N=43) 
mtDNA deletion level significantly decreases with the increase of mtDNA copy number (p=0.0006; R2=0.2464). 
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In all samples was then investigated the mtDNA integrity, intended as the number of intact 
molecules over the total number of mtDNA molecules per subject. This parameter was 
examined in relation with age, but only a barely significative decrease appeared in the total 
number of subjects (p=0.0477, R2=0.0493, fig. 15a). This significative change, indeed, was 
completely lost when data were analyzed by gender: both females and males did not reveal 
any significant variation in mtDNA integrity with age (p=0.1972, R2=0.0493 and p=0.1563, 
R2=0.0484, respectively). 
 
Figure 15: Regression analysis of mtDNA integrity as a function of age was performed in 80 DNA samples from 
liver biopsies. a.) In the total number of samples (N=80), mtDNA integrity significantly decreases with age 
(p=0.0477; R2=0.0493). b.) In females (N=37) mtDNA integrity level does not change significantly with age 
(p=0.1972; R2=0.0470). c.) In males (N=43) mtDNA integrity does not change significantly with age (p=0.1563; 
R2=0.0484). 
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4.1.4 Telomere length  
Telomere length was examined since telomeres shortening is a well-recognized marker of 
aging.  
As expected, telomere length significantly decreased during human liver aging (p=0.0000, 
R2=0.2415), also when genders were considered separately (females: p=0.0022, R2=0.2648 and 
males: p=0.0015, R2=0.2742), as shown in figure 16. 
 
Figure 16: Regression analysis of telomere length as a function of age was performed in 67 DNA samples from 
liver biopsies. a.) In the total number of samples (N=67), telomere length significantly decreases with age 
(p=0.0000; R2=0.2415). b.) In females (N=33) telomere length significantly decreases with age (p=0.0022; 
R2=0.2648). c.) In males (N=34) telomere length significantly decreases with age (p=0.0015; R2=0.2742). 
As in 2011 Sahin and colleagues reported an interaction between telomeres shortening and 
mitobiogenesis (Sahin et al., 2011), the possible relationship between telomere length and 
mtDNA deletion level, copy number and integrity were studied.  
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The regression analysis of telomere length and mtDNA copy number revealed a significant 
relationship in the total number of subjects (fig. 17a; p=0.0030, R2=0.1277): as copy number 
increases, telomeres become shorter. When analysis was performed by gender, this 
relationship was conserved in males (fig. 17b; p=0.0002, R2=0.3597), but not in females (fig. 
17c; p=0.4082, R2=0.0222). 
 
Figure 17: Regression analysis of mtDNA copy number as a function of telomere length was performed in 67 DNA 
samples from liver biopsies. a.) In the total number of samples (N=67), mtDNA copy number significantly 
decreases with telomere length (p=0.0030; R2=0.1277). b.) In females (N=33) mtDNA copy number does not 
change significantly with telomere length (p=0.4082; R2=0.0222). c.) In males (N=34) mtDNA DNA copy number 
significantly decreases with telomere length (p=0.0002; R2=0.3597). 
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Looking at mtDNA deletion level, the regression analysis showed a significant direct association 
between the two parameters (figure 18): as telomere length increases, mtDNA deletion level 
increases as well all the samples (p=0.0305, R2=0.0700). Considering gender separately, either 
females and males lost the significative relationship (p=0.0506, R2=0.1177 and p=0.2825, 
R2=0.0360, respectively), as figures 18b and 18c show. 
 
Figure 18: Regression analysis of mtDNA deletion level as a function of telomere length was performed in 67 DNA 
samples from liver biopsies. a.) In the total number of samples (N=67), mtDNA deletion level significantly 
increases with telomere length (p=0.0305; R2=0.1277). b.) In females (N=33) mtDNA deletion level does not 
change significantly with telomere length (p=0.0506; R2=0.1177). c.) In males (N=34) mtDNA DNA deletion level 
does not change significantly with telomere length (p=0.2825; R2=0.0360). 
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Finally also the possible connection among telomere length and mtDNA integrity was taken 
into account. In all samples and in particular in males, but not in females, there was a strong 
direct connection (p=0.0018, R2=0.1444; p=0.0069, R2=0.2128; p=0.0856, R2=0.0953, 
respectively): as telomere length increases, mtDNA integrity also increases (fig. 19). 
 
Figure 19: Regression analysis of mtDNA integrity as a function of telomere length was performed in 67 DNA 
samples from liver biopsies. a.) In the total number of samples (N=67), mtDNA integrity significantly increases 
with telomere length (p=0.0018; R2=0.1444). b.) In females (N=33) mtDNA integrity does not change significantly 
with telomere length (p=0.0856; R2=0.0953). c.) In males (N=34) mtDNA integrity significantly increases with 
telomere length (p=0.0069; R2=0.2128). 
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4.1.5 Gene expression analysis 
To further characterise the involvement of mtDNA rearrangements during the aging of human 
liver, the relative expression of some key genes involved in several mitochondrial pathways 
was evaluated in a subgroup of liver biopsies.  
The relative expression of each gene, determined by qPCR assays, was considered as function 
of age and to evaluate a possible gender difference, all analyses were conducted first in the 
total number of samples and then on females and males separately. 
From the regression analysis, shown in figure 20, emerged that among genes involved in 
mitochondrial biogenesis (pgc-1α, polɣ, nrf1, tfam, twinkle, sirt1, sirt3, tomm40, ppard), only 
nrf1 showed significative changes in its expression level, either when samples were considered 
all together (p=0.0013, R2=0.3555) or when gender was taken into account (p=0.0387, 
R2=0.2711 and p=0.0107, R2=0.5776, for females and males, respectively). 
 
Figure 20: Regression analysis of expression level of nrf1 as a function of age was performed in 26 cDNA samples 
from liver biopsies. a.) In the total number of samples (N=26), expression level of nrf1 significantly increases with 
age (p=0.0013; R2=0.3555). b.) In females (N=16) expression level of nrf1 significantly increases with age 
(p=0.0387; R2=0.2711). c.) In males (N=10) expression level of nrf1 significantly increases with age (p=0.0107; 
R2=0.5776). 
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Regarding mitochondrial dynamics (mfn2, fis1 and opa1), there were significant changes in 
relative expression levels. In particular, for mfn2 there was a significant increase in the total 
number of subjects (p=0.0104, R2=0.2349), that was completely lost both in females (p=0.0508, 
R2=0.2458) and males (p=0.1883, R2=0.1838) considered separately, as shown in figure 21. 
 
Figure 21: Regression analysis of expression level of mnf2 as a function of age was performed in 27 cDNA samples 
from liver biopsies. a.) In the total number of samples (N=27), expression level of mnf2 significantly increases 
with age (p=0.0104; R2=0.2349). b.) In females (N=16) does not change with age (p=0.0508; R2=0.2458). c.) In 
males (N=10) expression level of mnf2 does not change with age (p=0.1883; R2=0.1838). 
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The same result came from fis1 expression level. Indeed the expression level of fis1 
significantly increased with age in the total number of samples (p=0.0088, R2=0.2440; figure 
22a), but a gender difference appeared when data were analyzed by gender. The regression 
analysis in females revealed a significant increase in the expression level of fis1 (p=0.0132, 
R2=0.3649; figure 22b), while no significative difference emerged in males (p=0.2836, 
R2=0.1262; figure 22c). 
 
Figure 22: Regression analysis of expression level of fis1 as a function of age was performed in 27 cDNA samples 
from liver biopsies. a.) In the total number of samples (N=27), expression level of fis1 significantly increases with 
age (p=0.0088; R2=0.2440). b.) In females (N=16) expression level of fis1 significantly increases with age 
(p=0.0132; R2=0.3649). c.) In males (N=10) expression level of fis1 does not change with age (p=0.2836; 
R2=0.1262). 
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Finally, in the case of nuclear proteins that are involved in mitochondrial proteins quality 
control system, a significant increase in lonp expression level was found in the total number of 
subjects (p=0.0009, R2=0.3638). This increment was also maintained when analysis was 
conducted by gender, as figure 23 displays (p=0.0272, R2=0.3027 and p=0.0139, R2=0.5075, 
females and males respectively). 
 
Figure 23: Regression analysis of expression level of lonp as a function of age was performed in 27 cDNA samples 
from liver biopsies. a.) In the total number of samples (N=27), expression level of lonp significantly increases with 
age (p=0.0009; R2=0.3638). b.) In females (N=16) expression level of lonp significantly increases with age 
(p=0.0272; R2=0.3027). c.) In males (N=10) expression level of fis1 expression level of lonp significantly increases 
with age (p=0.0139; R2=0.5075). 
No significant changes with age emerged when analysing the relative gene expression of 
mitophagy (ambra1, beclin, pink1, parkin, atg16l and pik3cd), production of ROS (nos3), 
protection from ROS (sod1 and sod2) and hypoxia (hif-1α), neither in the total number of 
patients, nor in females, nor in males (data not shown). 
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4.2 Human Skeletal Muscle 
To study the role of mtDNA rearrangements in the aging of human skeletal muscle, mtDNA 
copy number, mtDNA deletion level, mtDNA integrity, telomere length and gene expression 
levels were evaluated using DNA and RNA isolated from Vastus lateralis muscle biopsies of two 
groups of subjects: healthy young (<40 years) and old (>65 years) subjects and patients with 
lower limbs mobility impairment (LMLL) underwent hip replacement surgery aged from 24 to 
96 years. These variables were analyzed in relation to age in each group of subjects and then in 
females and males separately to evaluate possible gender differences.  
4.2.1 Healthy subjects 
4.2.1.1 mtDNA copy number 
mtDNA copy number was measured in healthy subjects’ Vastus lateralis muscle biopsies. 
Figure 24 shows that there was a barely significative decrease in mtDNA copy number in 
healthy elderly subjects with respect to young ones (p=0.0448, Χ2=2.007). However, this 
difference in mtDNA copy number was not maintained when analysis was conducted by 
gender (p=0.1136, Χ2=1.582 and p=0.3139, Χ2=1.007, for females and males respectively). 
 
Figure 24: Analysis of mtDNA copy number in relation to age. To compare young (<40 years) and old (>65 years) 
subjects, Mann-Whitney test was applied. a.) In the total number of subjects (N=109) mtDNA relative copy 
number is barely significantly higher (p=0.0488; X2=2.007) in young subjects (N=36) than in old subjects (N=73). 
b.) In healthy females (N=56), any significant change is mtDNA relative copy number (p=0.1136; X2=1.582) 
between young (N=21) and old (N=32) subjects was observed. c.) In healthy males (N=53), mtDNA content does 
not significantly vary (p=0.3139; X2=1.007) between young (N=15) and old (N=38) subjects. 
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4.2.1.2 mtDNA deletion level 
No significative changes were found in mtDNA deletion level in total number of subjects 
(p=0.1758, Χ2=-1.252) and in males (p=0.5508, Χ2=0.597), while in females, a marginally 
significative increase in deletion level was found (p=0.0414, Χ2=-1.920, fig. 25b).  
 
Figure 25: Analysis of mtDNA deletion level in relation to age. To compare young (<40 years) and old (>65 years) 
subjects, Mann-Whitney test was applied. a.) In the total number of subjects (N=93) mtDNA deletion level is not 
significantly different (p=0.1758; X2=-1.252) between young (N=31) and old subjects (N=63). b.) In healthy females 
(N=50), mtDNA deletion level is significantly lower (p=0.0414; X2=-1.920) in young (N=19) with respect to old 
(N=31) subjects. c.) In healthy males (N=43), mtDNA deletion level does not significantly vary (p=0.5508; 
X2=0.597) between young (N=12) and old (N=31) subjects. 
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4.2.1.3 mtDNA integrity 
mtDNA integrity was found higher in healthy young than in elderly subjects (p=0.0012, 
Χ2=3.046). Also when samples were sorted by gender, mtDNA integrity was found still 
statistically different among young and elderly subjects, both in females (p=0.0265, Χ2=2.210) 
and males (p=0.0285, Χ2=2.120). Data are shown in figure 26. 
 
Figure 26: Analysis of mtDNA integrity in relation to age. To compare young (<40 years) and old (>65 years) 
subjects, Mann-Whitney test was applied. a.) In the total number of subjects (N=100) mtDNA integrity is 
significantly lower (p=0.0012; X2=3.046) in young (N=36) with respect to old subjects (N=64). b.) In healthy 
females (N=53), mtDNA integrity is significantly lower (p=0.0265; X2=2.210) in young (N=21) with respect to old 
(N=32) subjects. c.) In healthy males (N=47), mtDNA integrity is significantly lower (p=0.0285; X2=2.120) in young 
(N=15) with respect to old (N=32) subjects. 
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4.2.1.4 Telomere length 
Any significative differences emerged in telomere length between young and old healthy 
subjects, both in all samples (p=0.8570, Χ2=0.17; fig. 27a) and by gender (p=0.8078, Χ2=0.01 
and p=0.5034, Χ2=0.25, for females and males respectively; fig.27b and 27c). 
 
Figure 27: Analysis of telomere length in relation to age. To compare young (<40 years) and old (>65 years) 
subjects, Mann-Whitney test was applied. a.) In the total number of subjects (N=63) telomere length is not 
significantly different (p=0.8570; X2=0.17) between young (N=22) and old subjects (N=41). B.) In healthy females 
(N=33) telomere length is not significantly different (p=0.8078; X2=0.01) between young (N=12) and old subjects 
(N=21). c.) Also in healthy males (N=30), telomere length does not differ (p=0.5034; X2=0.25) between young 
(N=10) and old (N=20) subjects. 
Moreover, also studying possible relations between telomere shortening and mtDNA 
dysfunction, no significative association with telomere length emerged, neither for mtDNA 
copy number, nor for mtDNA deletion level and mtDNA integrity (data not shown).  
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4.2.1.5 Gene expression analysis 
A subgroup of healthy subjects biopsies was chosen to analyse the gene expression level of the 
same genes analyzed in liver samples (pgc-1α, polɣ, nrf1, tfam, twinkle, sirt1, sirt3, tomm40, 
ppard, mfn2, fis1, opa1, ambra1, beclin, pink1, parkin, atg16l, pik3cd, nos3, sod1, sod2, lonp, 
hif-1α). Each gene was compared between young (<40 years) and old (>65 years) healthy 
subjects. To evaluate a possible gender difference, all the analyses were then separately 
performed on females and males. 
Regarding genes involved in mitobiogenesis (pgc-1α, polɣ, nrf1, tfam, twinkle, sirt1, sirt3, 
tomm40, ppard), only the expression level of pgc1α, polγ and tfam were statistically different 
between young and old healthy subjects. In particular, the expression of pgc1α decreased in 
old healthy subjects (p=0.0002, Χ2=14.173) compared to young healthy and, also analysing 
females and males separately, this difference between was maintained (p=0.0038, Χ2=8.730 
and p=0.0172, Χ2=5.674, respectively; fig. 28).  
 
Figure 28: Analysis of expression level of pgc-1α in relation to age. To compare young (<40 years) and old (>65 
years) subjects, Kruskal-Wallis test was applied. a.) In the total number of subjects (N=28) expression level of pgc-
1α is significantly higher (p=0.0002; X2=14.173) in young (N=9) with respect to old subjects (N=19). b.) In healthy 
females (N=16) expression level of pgc-1α is significantly higher (p=0.0038; X2=8.730) in young (N=5) than in old 
subjects (N=11). c.) Also in healthy males (N=12), expression level of pgc-1α is significantly higher (p=0.0172; 
X2=5.674) in young (N=4) than in old (N=5) subjects. 
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As can be seen in figure 29, polγ expression level showed a significative decrease in elderly 
subjects compared to young when analysis was performed on all subjects (p=0.0067, Χ2=9.03), 
however this difference was weakly maintained only in males (p=0.0485, Χ2=5.69), when 
genders were considered singly. 
 
Figure 29: Analysis of expression level of polγ in relation to age. To compare young (<40 years) and old (>65 years) 
subjects, Kruskal-Wallis test was applied. a.) In the total number of subjects (N=23) expression level of polγ is 
significantly higher (p=0.0067; X2=9.03) in young (N=8) with respect to old subjects (N=15). b.) In healthy females 
(N=12) expression level of polγ does not change (p=0.0768; X2=3.75) between young (N=4) and old subjects 
(N=10). c.) In healthy males (N=9), expression level of polγ is significantly higher (p=0.0485; X2=5.69) in young 
(N=4) than in old (N=5) subjects. 
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Tfam expression level displayed a statistically significant decrease in elderly subjects with 
respect to young individuals (p=0.0095, Χ2=7.89) that was maintained in females (p=0.0155, 
Χ2=7.94), but not in males (p=0.1650, Χ2=2.21), as shown in fig. 30. 
 
Figure 30: Analysis of expression level of tfam in relation to age. To compare young (<40 years) and old (>65 
years) subjects, Kruskal-Wallis test was applied. a.) In the total number of subjects (N=27) expression level of 
tfam is significantly higher (p=0.0095; X2=7.89) in young (N=7) with respect to old subjects (N=20). b.) In healthy 
females (N=14) expression level of tfam is significantly higher (p=0.0155; X2=7.94) in young (N=3) than in old 
subjects (N=11). c.) In healthy males (N=13), expression level of tfam does not change (p=0.1650; X2=2.21) in 
young (N=4) than in old (N=9) subjects. 
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Also some genes involved in mitophagy were found to be expressed at different level in 
healthy young and elderly subjects. These gene are beclin, opa1 and pik3cd. The expression 
level of beclin was higher in young than in elderly (p=0.0065, Χ2=8.82), but when looking at 
gender, the decrease with age in its expression level was significant only in females (p=0.0039, 
Χ2=12.69) but not in males (p=0.3208, Χ2=1.08; data shown in fig. 31).  
 
Figure 31: Analysis of expression level of beclin in relation to age. To compare young (<40 years) and old (>65 
years) subjects, Kruskal-Wallis test was applied. a.) In the total number of subjects (N=27) expression level of 
beclin is significantly higher (p=0.0065; X2=8.82) in young (N=9) with respect to old subjects (N=18). b.) In healthy 
females (N=14) expression level of beclin is significantly higher (p=0.0039; X2=12.69) in young (N=5) than in old 
subjects (N=9). c.) In healthy males (N=13), expression level of beclin does not change (p=0.3208; X2=1.08) in 
young (N=4) than in old (N=9) subjects. 
Also for opa1 and pik3cd the expression level was higher in healthy young subjects than in 
elderly (p=0.0236, Χ2=2.264 and p=0.00164, Χ2=2.389, respectively), nevertheless dissimilarly 
from beclin, this difference in the expression level was maintained its statistical significant in 
males but not in females (opa1: p=0.0308, Χ2=2.160 and p=0.3952, Χ2=0.850; pik3cd: p=0.0247, 
Χ2=2.245, p=0.3603, Χ2=0.915, respectively). Data relative to opa1 and pik3cd are shown in 
figures 32 and 33 respectively. 
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Figure 32: Analysis of expression level of opa1 in relation to age. To compare young (<40 years) and old (>65 
years) subjects, Kruskal-Wallis test was applied. a.) In the total number of subjects (N=28) expression level of 
opa1 is significantly higher (p=0.0236; X2=2.264) in young (N=8) with respect to old subjects (N=20). b.) In healthy 
females (N=15) expression level of opa1 does not change (p=0.3952; X2=0.850) between young (N=4) and old 
subjects (N=11). c.) In healthy males (N=13), expression level of opa1 is significantly higher (p=0.0308; X2=2.160) 
in young (N=4) with respect to old subjects (N=9). 
 
Figure 33: Analysis of expression level of pik3cd in relation to age. To compare young (<40 years) and old (>65 
years) subjects, Kruskal-Wallis test was applied. a.) In the total number of subjects (N=28) expression level of 
pik3cd is significantly higher (p=0.0164; X2=2.399) in young (N=8) with respect to old subjects (N=20). b.) In 
healthy females (N=15) expression level of pik3cd does not change (p=0.3603; X2=0.915) between young (N=4) 
and old subjects (N=11). c.) In healthy males (N=13), expression level of pik3cd is significantly higher (p=0.0247; 
X2=2.245) in young (N=4) with respect to old subjects (N=9). 
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Finally, as displayed in figure 34, the expression level of nos3 was found significantly high in 
healthy young males compared to old males (p=0.0308, Χ2=4.667), while no significative 
difference emerged in the total number of healthy subjects and in females (p=0.1710, Χ2=1.874 
and p=0.4243, Χ2=0.638, respectively).  
 
Figure 34: Analysis of expression level of nos3 in relation to age. To compare young (<40 years) and old (>65 
years) subjects, Kruskal-Wallis test was applied. a.) In the total number of subjects (N=29) expression level of 
nos3 does not change (p=0.1710; X2=1.874) between young (N=9) and old subjects (N=20). b.) In healthy females 
(N=16) expression level of nos3 does not change (p=0.4243; X2=0.638) between young (N=5) and old subjects 
(N=11). c.) Only in healthy males (N=13), expression level of nos3 is significantly higher (p=0.0308; X2=4.667) in 
young (N=4) with respect to old subjects (N=9). 
Instead, any significant changes between the two age groups emerged in the expression level 
of genes involved in mitochondrial biogenesis (nrf1, tomm40, sirt1, twinkle, sirt3, ppard), 
mitochondrial dynamics (mfn2, fis1), mitophagy (ambra1, pink1, parkin, atg16l), protein 
quality control system (lonp), protection from ROS (sod1 and sod2) and hypoxia (hif-1α), 
neither in the total number of subjects, nor in females and in males (data not shown). 
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4.2.2 LLMI patients 
4.2.2.1 mtDNA copy number 
As can be observed in figure 35, regression analysis of mtDNA copy number in vastus lateralis 
biopsies of LLMI in function of age showed a significative decrease in total number of subjects 
(p=0.0055, R2=0.1497) and in males (p=0.0357, R2=0.1588), but not in females (p=0.2071, 
R2=0.0783). 
 
Figure 35: Regression analysis of mtDNA copy number as a function of age was performed in 50 DNA samples 
from muscle biopsies of LLMI patients. a.) In the total number of samples (N=50), mtDNA copy number 
significantly decreases with age (p=0.0055; R2=0.1497). b.) In females (N=22) mtDNA copy number does not 
change with age (p=0.2072; R2=0.0783). c.) In males (N=28) mtDNA copy number significantly decreases with age 
(p=0.0357; R2=0.1588). 
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4.2.2.2 mtDNA deletion level 
Figure 36 shows as a significative increment in mtDNA deletion level with age in patients males 
samples (p=0.0022, R2=0.3086), while no significative difference were revealed either in total 
number of patients (p=0.5669, R2=0.0070) and in females (p=0.2073, R2=0.0823).  
 
Figure 36: Regression analysis of mtDNA deletion level as a function of age. a.) In the total number of patients 
(N=49), mtDNA deletion level does not significantly change with age (p=0.5669; R2=0.0070). b.) In females (N=21) 
mtDNA deletion level does not significantly change with age (p=0.2073; R2=0.0823). c.) In males (N=28) mtDNA 
deletion level significantly increases with age (p=0.0022; R2=0.3086). 
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4.2.2.3  mtDNA integrity 
With age, in LLMI patients, there was a significative decrement in mtDNA integrity in all 
samples (p=0.0271, R2=0.1039) and in males (p=0.0195, R2=0.2072), but not in females 
(p=0.7088, R2=0.0075), as shown in figure 37. 
 
Figure 37: Regression analysis of mtDNA integrity as a function of age. a.) In the total number of patients (N=47), 
mtDNA integrity significantly decreases with age (p=0.0271; R2=0.1039). b.) In females (N=21) mtDNA integrity 
does not significantly change with age (p=0.7088; R2=0.0075). c.) In males (N=26) mtDNA integrity significantly 
increases with age (p=0.0195; R2=0.2072). 
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4.2.2.4 Telomere length 
Regression analysis of telomere length in function of age in DNA samples from LLMI patients 
biopsies did not underlie any statistical significant change, neither in total number of samples 
(p=0.1528, R2=0.0439) nor in patients divided by gender (p=0.8639, R2=0.0017 and p=0.0649, 
R2=0.1250, for females and males, respectively) as figure 38 shows.  
 
Figure 38: Regression analysis of telomere length as a function of age. a.) In the total number of patients (N=48), 
telomere length does not with age (p=0.1528; R2=0.0439). b.) In females (N=20) telomere length does not with 
age (p=0.8639; R2=0.0017). c.) In males (N=28) telomere length does not with age (p=0.0649; R2=0.1250). 
Also the correlation analysis between telomere length and mtDNA copy number, deletion level 
and integrity did not exhibit any significative association, also when analysis were performed 
by gender (data not shown). 
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4.2.2.5 Gene expression analysis 
The gene expression analysis of LLMI patients muscle biopsies was conducted in a subgroup of 
samples at different age (13-94 years).  
Regarding mitobiogenesis, among pgc-1α, polɣ, nrf1, tfam, twinkle, sirt1, sirt3, tomm40, ppard, 
only tfam and sirt1 showed statistically significant changes in expression level. In particular, 
the expression level of tfam significantly decreased with age only in females (p=0.0171, 
R2=0.3894), but not in males (p=0.4460, R2=0.0492) and in all samples (p=0.3117, R2=0.0393), 
as displayed in figure 39.  
 
Figure 39: Regression analysis of expression level of tfam as a function of age. a.) In the total number of patients 
(N=28), expression level of tfam does not change with age (p=0.3117; R2=0.0393). b.) In females (N=14) 
expression level of tfam significantly decreases with age (p=0.0171; R2=0.3894). c.) In males (N=14) expression 
level of tfam does not change with age (p=0.4460; R2=0.0492). 
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For sirt1, instead, there was a significative increment in the expression level of all samples 
(p=0.0353, R2=0.1787; fig. 40a), that was completely lost when analysis was conducted by 
gender (for females: p=0.2367, R2=0.1368; for males: p=0.1199, R2=0.2054; figures 40b and 
40c). 
 
Figure 40: Regression analysis of expression level of sirt1 as a function of age. a.) In the total number of patients 
(N=25), expression level of sirt1 significantly increases with age (p=0.0353; R2=0.1787). b.) In females (N=12) 
expression level of sirt1 does not change with age (p=0.2367; R2=0.1368). c.) In males (N=13) expression level of 
sirt1 does not change with age (p=0.1199; R2=0.2054). 
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From the regression analysis also emerged a significant decrease of the expression level of 
beclin with age in both total number of patients (p=0.0161, R2=0.1964, figure 41a) and females 
(p=0.0282, R2=0.3192), but not in males (p=0.3352, R2=0.0775). 
 
Figure 41: Regression analysis of expression level of beclin as a function of age. a.) In the total number of patients 
(N=29), expression level of beclin significantly decreases with age (p=0.0161; R2=0.1964). b.) In females (N=15) 
expression level of beclin significantly decreases with age (p=0.0282; R2=0.3192). c.) In males (N=14) expression 
level of beclin does not change with age (p=0.3352; R2=0.0775). 
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Also pink1, another gene involved in mitophagy, showed a significant decrease with age in 
total number of samples (p=0.0179, R2=0.1906, figure 42a), and like beclin, when analysis was 
performed by gender, the decrease was significative in females (p=0.0378, R2=3121, figure 
42b) but not in males (p=0.2553, R2=0.0982, figure 42c). 
 
Figure 42: Regression analysis of expression level of pink1 as a function of age. a.) In the total number of patients 
(N=29), expression level of pink1 significantly decreases with age (p=0.0179; R2=0.1906). b.) In females (N=14) 
expression level of pink1 significantly decreases with age (p=0.0378; R2=0.3121). c.) In males (N=15) expression 
level of pink1n does not change with age (p=0.2553; R2=0.0982). 
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Another gene, codifying for superoxide dismutase 1 (sod1) displayed significant decrement in 
its expression level with age only in males (p=0.0078, R2=0.4591, as shown in figure 43), but 
not in the total number of subjects and in females (p=0.0527, R2=0.1275 and p=0.2970, 
R2=0.0832, respectively; data not shown). 
 
Figure 43: Regression analysis of expression level of pink1 as a function of age in males (N=13). The expression 
level of pink1n significantly decreases with age (p=0.0078; R2=0.4591). 
Any significant difference with age emerged from analysis of the expression level of genes 
involved in mitochondrial biogenesis (pgc1α, polγ, nrf1, tomm40, twinkle, sirt3, ppard), 
mitochondrial dynamics (mfn2, fis1, opa1,), mitophagy (ambra1, pik3cd, parkin, atg16l), 
protein quality control system (lonp), protection from ROS (sod2), production of ROS (nos3) 
and hypoxia (hif-1α), neither in the total number of patients, nor in females and in males (data 
not shown). 
  
66 
 
4.3 Adipose Tissue 
4.3.1 mtDNA copy number 
mtDNA copy number was quantified in 19 DNA samples from adipose tissue biopsies, coming 
from LLMI patients biopsies. 
Any statistically significant difference emerged from regression analysis of mtDNA copy 
number and age, both in the total number of samples (p=0.2854, R2=0.0668) and by gender 
analysis (for females: p=0.4406, R2=0.0871; for males: p=0.5385, R2=0.0491), as displayed in 
figure 44.  
 
Figure 44: Regression analysis of mtDNA copy number as a function of age was performed in 19 DNA samples 
from adipose tissue biopsies. a.) In the total number of samples (N=19), mtDNA copy number does not change 
with age (p=0.2854; R2=0.0668). b.) In females (N=9) mtDNA copy number does not change with age (p=0.4406; 
R2=0.0871). c.) In males (N=10) mtDNA copy number integrity does not change with age (p=0.5385; R2=0.0491). 
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4.3.2 mtDNA deletion level 
As can be seen in figure 45, in adipose tissue no significative difference was found with age in 
mtDNA deletion level in all samples (p=0.4471, R2=0.0344) and also in samples divided by 
gender (p=0.0537, R2=0.4339; p=0.6240, R2=0.0315, for females and males, respectively). 
 
Figure 45: Regression analysis of mtDNA deletion level as a function of age was performed in 19 DNA samples 
from adipose tissue biopsies. a.) In the total number of samples (N=19), mtDNA deletion level does not change 
with age (p=0.4471; R2=0.0344). b.) In females (N=9) mtDNA deletion level does not change with age (p=0.0537; 
R2=0.4339). c.) In males (N=10) mtDNA deletion level integrity does not change with age (p=0.6240; R2=0.0315). 
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4.3.3 mtDNA integrity 
From regression analysis of mtDNA integrity with age in adipose tissue samples, no 
significative changes emerged both in total number of samples (p=0.2384, R2=0.0807) and in 
samples divided by gender (for females: p=0.2984, R2=0.1527; for males: p=0.6109, 
R2=0.0338), as can be observed in figure 46. 
 
Figure 46: Regression analysis of mtDNA integrity as a function of age was performed in 19 DNA samples from 
adipose tissue biopsies. a.) In the total number of samples (N=19), mtDNA integrity does not change with age 
(p=0.2384; R2=0.0807). b.) In females (N=9) mtDNA integrity does not change with age (p=0.2984; R2=0.1527). c.) 
In males (N=10) mtDNA integrity does not change with age (p=0.6109; R2=0.0338). 
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4.3.4 Telomere length 
In DNA samples from adipose tissue was also analyzed telomere length. Also for this 
parameter, no significative difference was found with regression analysis with age in total 
samples (p=0.5888, R2=0.0187) and both in females (p=0.4284, R2=0.0917) and males 
(p=0.8622, R2=0.0046) separately. These data can be seen in figure 47. 
 
Figure 47: Regression analysis of telomere length as a function of age was performed in 19 DNA samples from 
adipose tissue biopsies. a.) In the total number of samples (N=19), telomere length does not change with age 
(p=0.5888; R2=0.0187). b.) In females (N=9) telomere length does not change with age (p=0.4284; R2=0.0917). c.) 
In males (N=10) telomere length does not change with age (p=0.6109; R2=0.0046). 
Subsequently, was investigated the relation between telomere length and mtDNA parameters 
in order to understand the possible relation of telomere shortening and mitochondrial 
dysfunction. Nevertheless the regression analysis did not highlight any statistically significant 
relation, neither in the total number of subjects nor in females or males (data not shown). 
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4.3.5 Gene expression analysis 
To further characterise the involvement of mtDNA rearrangements during the aging of human 
adipose tissue, the relative expression of key genes for mitobiogenesis (pgc-1α, polɣ, nrf1, 
tfam, twinkle, sirt1, sirt3, tomm40, ppard), for fusion and fission processes (mfn2, fis1 and 
opa1), for mitophagy (ambra1, beclin, pink1, parkin, atg16l and pik3cd), for production of ROS 
(nos3), for protection from ROS (sod1 and sod2), for the protein quality control system (lonp) 
and for hypoxia (hif-1α) studied in liver and muscle biopsies was evaluated in samples from 
adipose tissue.  
Like for liver and muscle samples, also in this case the relative expression of each gene was 
considered as function of age first in the total number of samples and then separately on 
females and males. 
For genes involved in mitobiogenesis (pgc-1α, polɣ, nrf1, tfam, twinkle, sirt1, sirt3, tomm40, 
ppard), only for twinkle and for nrf1 were found significative differences with age. However, 
for twinkle the statistical significant change in expression level was only marginal in the total 
number of subjects (p=0.0431, R2=0.2318) and completely lost when data were analyzed by 
gender (for females: p=0.0607, R2=0.4161; for males: p=0.1169, R2=0.3135), as shown in figure 
48. 
 
Figure 48: Regression analysis of expression level of twinkle as a function of age was performed in 18 cDNA 
samples from adipose tissue biopsies. a.) In the total number of samples (N=18), expression level of twinkle 
significantly decreases with age (p=0.0431; R2=0.2318). b.) In females (N=9) expression level of twinkle does not 
change with age (p=0.0607; R2=0.416). c.) In males (N=9) expression level of twinkle does not change with age 
(p=0.1169; R2=0.3135). 
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Conversely for nrf1, significative increases were found in the total number of samples 
(p=0.0169, R2=0.3248) and in females (p=0.0143, R2=0.5999), but not in males, where no 
significative difference with age emerged (p=0.1730, R2=0.2849), as can be seen in figure 49. 
 
Figure49: Regression analysis of expression level of nrf1 as a function of age was performed in 18 cDNA samples 
from adipose tissue biopsies. a.) In the total number of samples (N=18), expression level of nrf1 significantly 
increases with age (p=0.0169; R2=0.3248). b.) In females (N=9) expression level of nrf1 significantly increases with 
age (p=0.0143; R2=0.5999). c.) In males (N=9) expression level of nrf1 does not change with age (p=0.1730; 
R2=0.2849). 
Regarding genes for mitophagy, significative increments with age were found in the expression 
level of pink1 and ambra. In particular, for both these genes, the increment was significative in 
all samples (for pink1: p=0.0046, R2=0.4045; for ambra: p=0.0306, R2=0.2601) and in females 
(for pink1: p=0.0294, R2=0.5154; for ambra: p=0.0386, R2=0.4798), but not in males (for pink1: 
p=0.0638, R2=0.4086; for ambra: p=0.3147, R2=0.1435). Figure 50 shows data relative to pink1, 
while figure 51 shows those for ambra. 
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Figure50: Regression analysis of expression level of pink1 as a function of age was performed in 18 cDNA samples 
from adipose tissue biopsies. a.) In the total number of samples (N=18), expression level of pink1 significantly 
increases with age (p=0.0046; R2=0.4045). b.) In females (N=9) expression level of pink1 significantly increases 
with age (p=0.0294; R2=0.5154). c.) In males (N=9) expression level of pink1 does not change with age (p=0.0638; 
R2=0.4086). 
 
Figure51: Regression analysis of expression level of ambra as a function of age was performed in 18 cDNA 
samples from adipose tissue biopsies. a.) In the total number of samples (N=18), expression level of ambra 
significantly increases with age (p=0.0306; R2=0.2601). b.) In females (N=9) expression level of ambra significantly 
increases with age (p=0.0386; R2=0.4798). c.) In males (N=9) expression level of ambra does not change with age 
(p=0.3147; R2=0.1435). 
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Figure 52 shows as also for nos3, a gene involved in the production of ROS, a significative 
increment with age was found in all samples and in females (p=0.0320, R2=0.2565; p=0.0288, 
R2=0.5180, respectively), but not in males (p=0.2736, R2=0.1678).  
 
Figure52: Regression analysis of expression level of nos3 as a function of age was performed in 18 cDNA samples 
from adipose tissue biopsies. a.) In the total number of samples (N=18), expression level of nos3 significantly 
increases with age (p=0.0320; R2=0.2565). b.) In females (N=9) expression level of nos3 significantly increases with 
age (p=0.0288; R2=0.5180). c.) In males (N=9) expression level of nos3 does not change with age (p=0.2736; 
R2=0.1678). 
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Finally, as shown in figure 53, the expression level of sod1 was found significantly increased 
with age in the total number of subjects (p=0.0283, R2=0.2665), but analyzing data by gender, 
no statistically significant differences were detected neither in females (p=0.1387, R2=0.2851; 
data not shown) nor in males (p=0.1584, R2=0.2626; data not shown). 
 
Figure53: Regression analysis of expression level of sod1 as a function of age in all samples (N=18). The 
expression level of sod1n significantly decreases with age (p=0.0283; R2=0.2665). 
Any statistically significant difference neither in all samples nor in by gender analysis was 
found for gene involved in mitobiogenesis (pgc1α, polγ, tfam, tomm40, sirt1, sirt3, ppard), in 
mitochondrial dynamics (mfn2, fis1, opa1), in protein quality control system (lonp), in 
mitophagy (beclin1, parkin, pik3cd and atg16l), in protection from ROS (sod2) and finally in 
hypoxia (hif-1α). These data are not shown. 
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4.4 Tissue comparison 
In order to evaluate possible differences between the studied tissues (liver, healthy muscle, 
LLMI patients muscles and adipose tissue), mtDNA copy number, deletion level, integrity and 
telomere length as well as gene expression of the examined nuclear genes were compared 
among tissues independently from age in the total number of samples and then in females and 
males separately. In table 17, are reported the assigned tissue index. 
Tissue Index Tissue Number of samples (N)  Gender (N) 
    M F 
0 Liver 28  12 16 
1 Healthy muscle 29  14 15 
2 Patient muscle 30  15 15 
3 Adipose tissue 19  10 9 
Table 17: Tissue index assigned to every type of tissues samples and number of samples considered for each 
tissue. 
4.4.1 mtDNA copy number 
mtDNA copy number was found significantly different between the examined tissues. In 
particular, in livers samples, mtDNA copy number was significantly lower than in muscles, both 
healthy subjects and patients, and than in adipose tissue (fig. 54). 
 
Figure 54: Comparison of mtDNA copy number among liver (0), muscle from healthy subjects (1), muscle from 
LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied; mtDNA copy 
number is significantly lower in liver than in muscle from healthy subjects (p=0.0001), in muscle from LLMI 
patients (p=0.0001) and in adipose tissue (p=0.0001). 
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mtDNA copy number was found different between these tissues also when gender was 
considered separately: it was lower in livers samples than in others tissues both in females and 
in males, as shown in fig. 55.  
 
Figure 55: Comparison of mtDNA copy number among liver (0), muscle from healthy subjects (1), muscle from 
LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied. In the left panel are 
represented females, whose mtDNA copy number is significantly lower in liver than in muscle from healthy 
subjects (p=0.0001), in muscle from LLMI patients (p=0.0002) and in adipose tissue (p=0.0004). In the right panel 
are represented males, whose mtDNA copy number is significantly lower in respect to muscle from healthy 
subjects (p=0.0035), to muscle from LLMI patients (p=0.0001) and to adipose tissue (p=0.0066). 
4.4.2 mtDNA deletion level 
As fig. 56 shows, no significative difference in mtDNA deletion level was found among liver, 
muscle and adipose tissue (p=0.3139), even when comparing tissues one to each other and 
considering genders separately.  
 
Figure 56: Comparison of mtDNA deletion level among liver (0), muscle from healthy subjects (1), muscle from 
LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied; mtDNA deletion 
level does not differ among the tissues considered (p=0.3139).  
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4.4.3 mtDNA integrtiy 
When investigating all samples and sample divided by gender, mtDNA integrity differenced in a 
significant way among tissues and in livers samples was significantly lower than in muscle and 
adipose tissues, both in the total number of samples and in samples divided by gender. Figure 
57 and figure 58 illustrate these results. 
 
Figure 57: Comparison of mtDNA integrity among liver (0), muscle from healthy subjects (1), muscle from LLMI 
patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied; mtDNA integrity is 
significantly lower in liver than in muscle from healthy subjects (p=0.0001), in muscle from LLMI patients 
(p=0.0001) and in adipose tissue (p=0.0001). 
 
Figure 58: Comparison of mtDNA integrity among liver (0), muscle from healthy subjects (1), muscle from LLMI 
patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied. In the left panel are 
represented females, whose mtDNA integrity is significantly lower in liver than in muscle from healthy subjects 
(p=0.0004), in muscle from LLMI patients (p=0.0012) and in adipose tissue (p=0.0011). In the right panel are 
represented males, whose mtDNA integrity is significantly lower in respect to muscle from healthy subjects 
(p=0.0040), to muscle from LLMI patients (p=0.0006) and to adipose tissue (p=0.0071). 
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4.4.4 Telomere length 
Regarding telomere length, no significative differences were found among tissues (p=0.0620; 
fig. 59). However, when comparing tissue one to each other and considering genders 
separately, a significative difference between telomere length in liver and adipose tissue 
emerged: telomere length in females liver was significantly higher than in females adipose 
tissue, as shown in fig. 60. 
 
Figure 59: Comparison of telomere length among liver (0), muscle from healthy subjects (1), muscle from LLMI 
patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied; telomere length level 
does not differ among the tissues considered (p=0.0620).  
 
Figure 60: Comparison of telomere length among liver (0), muscle from healthy subjects (1), muscle from LLMI 
patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied. In the left panel are 
represented females, whose telomere length is significantly higher in liver than in adipose tissue (p=0.0017). In 
the right panel are represented males, whose telomere length does not differ among the considered tissues. 
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4.4.5 Gene expression 
The relative expression of the aforementioned nuclear mitochondrial-related genes has been 
also compared among liver, muscle (from healthy subjects and patients) and adipose tissue, to 
identify possible different mechanisms involved in mtDNA rearrangements. The analyses were 
conducted independently to age, first in the total number of subjects and then in females and 
males separately to evaluate a possible gender difference. 
4.4.5.1 Pgc1-α 
The expression level of pgc1-α was found significantly higher in muscle from healthy subjects 
than in liver and adipose tissue. Also the expression level of pgc1-α in muscle from LLMI 
patients significantly differed from those of liver and adipose tissue. However also between 
liver and adipose tissue the expression level of pgc1-α was significantly different, greater for 
the former than the latter, as shown in figure 61.  
 
Figure 61: Comparison of pgc-1α relative expression level among liver (0), muscle from healthy subjects (1), 
muscle from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied; pgc-1α 
relative expression level is significantly lower in liver than in muscle from healthy subjects (p=0.0001), in muscle 
from LLMI patients (p=0.0001) and in adipose tissue (p=0.0001). Pgc-1α relative expression level is significantly 
different among adipose tissue and muscle from healthy subjects (p=0.0001) and from LLMI patients (p=0.0001). 
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When genders were considered separately, the different expression levels were maintained 
both in males and females, but in females, the pgc1-α expression level was different also 
between healthy subjects and LLMI patients muscles, as illustrated in figure 62. 
 
Figure 62: Comparison of pgc-1α relative expression level among liver (0), muscle from healthy subjects (1), 
muscle from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied. In the 
left panel are represented females: pgc-1α relative expression level is significantly different among liver and 
muscle, both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0001), between liver and adipose 
tissue (p=0.0003), between muscle from healthy subjects and muscle from LLMI patients (p=0.0034), between 
muscle from healthy subjects and adipose tissue (p=0.0001) and finally between adipose tissue and muscle from 
LLMI patients (p=0.0001). In the right panel are represented males: pgc-1α relative expression level is 
significantly different among liver and muscle, both from healthy subjects (p=0.0003) and from LLMI patients 
(p=0.0001), between liver and adipose tissue (p=0.0001), and finally among adipose tissues and muscles, both 
from healthy subjects (p=0.0001) and from LLMI patients (p=0.0001). 
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4.4.5.2 Polγ  
Polγ expression level was found significantly different between all tissues considered: it was 
higher in muscles from patients than in samples from healthy subjects muscle, from liver and 
from adipose tissue. However, in healthy subjects the expression level was greater than in liver 
and in adipose tissue and also between liver and adipose tissue the expression level of polγ 
was significantly different, greater for the former and lower the latter. Data are presented in 
figure 63. 
 
Figure 63: Comparison of polγ relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied; polγ relative 
expression level is significantly lower in liver than in muscle from healthy subjects (p=0.0001), in muscle from 
LLMI patients (p=0.0001) and higher than in adipose tissue (p=0.0001). Polγ relative expression level is 
significantly different between muscle from healthy subjects and LLMI patients (p=0.0001), between muscle from 
healthy subjects and adipose tissue (p=0.0001) and finally between muscle from LLMI patients and adipose tissue 
(p=0.0001). 
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When data were analyzed by gender, the difference in the expression level between muscles 
from healthy subjects and from patients was lost both in females and in males, while all the 
others significative differences between tissue were maintained (fig. 64). 
 
Figure 64: Comparison of polγ relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied. In the left 
panel are represented females: polγ relative expression level is significantly different among liver and muscle, 
both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0001), between liver and adipose tissue 
(p=0.0001), among adipose tissue and muscles, both from healthy subjects (p=0.0001) and from LLMI patients 
(p=0.0001). In the right panel are represented males: polγ relative expression level is significantly different 
among liver and muscle, both from healthy subjects (p=0.0007) and from LLMI patients (p=0.0001), between liver 
and adipose tissue (p=0.0001), among adipose tissue and muscles, both from healthy subjects (p=0.0001) and 
from LLMI patients (p=0.0001). 
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4.4.5.3 Tfam 
The expression level of tfam in livers was significantly the highest among tissues, following in 
order by the expression level of muscles from healthy subjects, that was higher than that from 
patients and that from adipose tissue. However, also LLMI patients had a higher tfam 
expression level than adipose tissue, whose expression level was significantly the lowest (fig. 
65).  
 
Figure 65: Comparison of tfam relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied; tfam relative 
expression level is significantly higher in liver than in muscle from healthy subjects (p=0.0002), in muscle from 
LLMI patients (p=0.0001) and in adipose tissue (p=0.0001). Tfam relative expression level is significantly different 
between muscle from healthy subjects and LLMI patients (p=0.0012), between muscle from healthy subjects and 
adipose tissue (p=0.0001) and finally between muscle from LLMI patients and adipose tissue (p=0.0001). 
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Some differences were lost when data were analyzed by gender, as shown in fig. 66, in 
particular both in males and females the difference between the two group of muscles was no 
more significant and only in females the differences between liver and muscle from healthy 
subjects was not significant.  
 
Figure 66: Comparison of tfam relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied. In the left 
panel are represented females: tfam relative expression level is significantly different between liver and muscle 
from LLMI patients (p=0.0001), between liver and adipose tissue (p=0.0001), among adipose tissue and muscle, 
both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0001). In the right panel are represented 
males: tfam relative expression level is significantly different among liver and muscle, both from healthy subjects 
(p=0.0033) and from LLMI patients (p=0.0001),between liver and adipose tissue (p=0.0001), among adipose tissue 
and muscles, both from healthy subjects (p=0.0004) and from LLMI patients (p=0.0001). 
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4.4.5.4 Nrf1 
In healthy subjects muscles the expression level of nrf1 was significantly greater than in patient 
muscles, in livers and in adipose tissues. Moreover, the differences in the expression level 
between LLMI patients, livers and adipose tissue were significative, as the difference between 
livers and adipose tissue (fig. 67).  
 
Figure 67: Comparison of nrf1 relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied; nrf1 relative 
expression level is significantly different among liver and muscle, both from healthy subjects (p=0.0002) and from 
LLMI patients (p=0.0001) and between liver and adipose tissue (p=0.0011). Nrf1 relative expression level is 
significantly different between muscle from healthy subjects and LLMI patients (p=0.0004), between muscle from 
healthy subjects and adipose tissue (p=0.0001) and finally between muscle LLMI patients and adipose tissue 
(p=0.0001). 
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Data analyzed by gender showed some differences between females and males. In particular, 
in females were lost the significative differences between healthy subjects and patient 
muscles, and among the expression level in livers and adipose tissues. Instead in males, only 
the difference in livers and adipose tissue nfr1 expression level was not significative (fig. 68).  
 
Figure 68: Comparison of nrf1 relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied. In the left 
panel are represented females: nrf1 relative expression level is significantly different among liver and muscle, 
both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0005) and among adipose tissues and 
muscles, both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0001). In the right panel are 
represented males: nrf1 relative expression level is significantly different among liver and muscle, both from 
healthy subjects (p=0.0021) and from LLMI patients (p=0.0078), between muscle from healthy subjects and 
muscle from LLMI patients (p=0.0064), among adipose tissue and muscles, both from healthy subjects (p=0.0039) 
and from LLMI patients (p=0.0027). 
  
87 
 
4.4.5.5 Twinkle  
From the analysis of all samples, the expression level of twinkle was significantly different 
between livers and muscles (both healthy subjects and patients) and between adipose tissue 
and both groups of muscles, as illustrated in fig. 69.  
 
Figure 69: Comparison of twinkle relative expression level among liver (0), muscle from healthy subjects (1), 
muscle from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied; twinkle 
relative expression level is significantly different among liver and muscle, both from healthy subjects (p=0.0001) 
and from LLMI patients (p=0.0001), and among adipose tissue and muscles, both from healthy subjects 
(p=0.0001) and from LLMI patients (p=0.0001). 
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The same significant differences were found in females and males examined separately: the 
expression level of twinkle was lower in adipose tissues and in livers than in the groups of 
muscles, but no differences among livers and adipose tissues emerged. Figure 70 shows data 
relative to twinkle expression levels in females and males.  
 
Figure 70: Comparison of twinkle relative expression level among liver (0), muscle from healthy subjects (1), 
muscle from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied. In the 
left panel are represented females: twinkle relative expression level is significantly different among liver and 
muscle, both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0005) and among adipose tissue and 
muscles, both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0003). In the right panel are 
represented males: twinkle relative expression level is significantly different among liver and muscle, both from 
healthy subjects (p=0.0004) and from LLMI patients (p=0.0001) and among adipose tissue and muscles, both from 
healthy subjects (p=0.0006) and from LLMI patients (p=0.0001). 
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4.4.5.6 Sirt1 
As fig. 71 shows, the dissimilarities in sirt1 expression level thought the investigated tissue 
were similar to those observed for nrf1: sirt1 was highly expressed in muscle from healthy 
subjects than in muscles from LLMI patients, from livers and from adipose tissues. However, 
there was no significative difference in sirt1 expression level between livers and LLMI patients, 
while both of their expression levels were significantly higher than that of adipose tissues. 
 
Figure 71: Comparison of sirt1 relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied; sirt1 relative 
expression level is significantly different between liver and muscle from healthy subjects (p=0.0001), between 
liver and adipose tissue (p=0.0001), between muscle from healthy subjects and muscle from LLMI patients 
(p=0.0001), and among adipose tissues and muscles, both from healthy subjects (p=0.0001) and from LLMI 
patients (p=0.0001). 
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The same pattern of differences emerged when data were analyzed by gender, as shown in fig. 
72. 
 
Figure 72: Comparison of sirt1 relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied. In the left 
panel are represented females: sirt1 relative expression level is significantly different between liver and muscle 
from healthy subjects (p=0.0004) and between liver and adipose tissue (p=0.0003). Muscle from healthy subjects 
significantly differs to muscle from LLMI patients (p=0.0009), and finally significative differences exist among 
adipose tissue and muscles, both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0001). In the 
right panel are represented males: sirt1 relative expression level is significantly different between liver and 
muscle from healthy subjects (p=0.0047) and between liver and adipose tissue (p=0.0037). Muscle from healthy 
subjects significantly differs to muscles from LLMI patients (p=0.0076), and finally significative differences exist 
among adipose tissue and muscles, both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0001). 
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4.4.5.7 Mfn2 
Regarding the expression level of mfn2, it was found different between all the tissues 
considered: the expression levels of mfn2 in livers was dissimilar from that of both the groups 
of muscle and from that of adipose tissue, that in turn was lower than that of muscles, that, 
finally, were different also among them (fig. 73).  
 
Figure 73: Comparison of mfn2 relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied; mfn2 relative 
expression level is significantly different among liver and muscle, both from healthy subjects (p=0.0001) and from 
LLMI patients (p=0.0001) and between liver and adipose tissue (p=0.0001). Mnf2 relative expression level is 
significantly different also between muscle from healthy subjects and from LLMI patients (p=0.0007), and among 
adipose tissue and muscles, both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0001). 
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These divergences in the expression level of mfn2 were the same in females analyzed alone, 
whereas in males the difference between the two groups of muscles disappeared, as it can be 
seen in fig. 74. 
 
Figure 74: Comparison of mfn2 relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied. In the left 
panel are represented females: mfn2 relative expression level is significantly different among liver and muscle, 
both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0001), between liver and adipose tissue 
(p=0.0002), between muscle from healthy subjects and muscle from LLMI patients (p=0.0023), and finally among 
adipose tissue and muscles, both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0001). In the 
right panel are represented males: mfn2 relative expression level is significantly different among liver and 
muscle, both from healthy subjects (p=0.0002) and from LLMI patients (p=0.0001), between liver and adipose 
tissue (p=0.0001), and finally among adipose tissue and muscles, both from healthy subjects (p=0.0001) and from 
LLMI patients (p=0.0001). 
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4.4.5.8 Opa1 
Opa1 expression level was higher in liver samples than in adipose tissue samples, that showed 
a lower expression level also compared to both groups of muscle samples (fig. 75).  
 
Figure 75: Comparison of opa1 relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied; opa1 relative 
expression level is significantly different between liver and muscle from healthy subjects (p=0.0002), between 
liver and adipose tissue (p=0.0001), and among adipose tissue and muscles, both from healthy subjects 
(p=0.0001) and from LLMI patients (p=0.0001). 
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When genders were considered independently one to the other, a mismatched pattern of 
differences emerged, as shown in fig. 76. In more detail, in females, opa1 was significantly less 
expressed in adipose tissue with respect to liver and muscle. In males, instead, there were 
significative differences between the livers and the others tissues, and among the patients 
muscles and the adipose tissues. 
 
Figure 76: Comparison of opa1 relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied. In the left 
panel are represented females: opa1relative expression level is significantly different between adipose tissue and 
liver (p=0.0001) and among adipose tissue and muscles, both from healthy subjects (p=0.0004) and from LLMI 
patients (p=0.0005). In the right panel are represented males: opa1 relative expression level is significantly 
different among liver and muscle, both from healthy subjects (p=0.0006) and from LLMI patients (p=0.0040), 
between liver and adipose tissue (p=0.0001), and finally between adipose tissue and muscle from LLMI patients 
(p=0.0003). 
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4.4.5.9 Fis1 
Significative differences emerged in the expression level of fis1, in particular fis1 was less 
expressed in liver and adipose tissue with respect to both the groups of muscles, nevertheless, 
the expression level of fis1 in liver was higher than in adipose tissue, as can be seen in fig. 77. 
 
Figure 77: Comparison of fis1 relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied; fis1 relative 
expression level is significantly different among liver and muscle, both from healthy subjects (p=0.0001) and from 
LLMI patients (p=0.0001) and between liver and adipose tissue (p=0.0004). Fis1 relative expression level is also 
significantly different among adipose tissue and muscles, both from healthy subjects (p=0.0001) and from LLMI 
patients (p=0.0001). 
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The same differences emerged when data were analyzed by gender, but both in males and in 
females, the difference in fis1 expression level between liver samples and adipose tissue 
samples was not still significant, whereas all the others differences were significantly 
maintained, as illustrated in fig. 78. 
 
Figure 78: Comparison of fis1 relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied. In the left 
panel are represented females: fis1 relative expression level is significantly different among liver and muscle, 
both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0001) and among adipose tissue and muscles, 
both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0003). In the right panel are represented 
males: fis1 relative expression level is significantly different among liver and muscle, both from healthy subjects 
(p=0.0047) and from LLMI patients (p=0.0001) and among adipose tissue and muscles, both from healthy subjects 
(p=0.0001) and from LLMI patients (p=0.0001). 
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4.4.5.10 Pink1 
Pink1 was less expressed in adipose tissue with respect to muscle and liver, but the liver 
expression level of pink1 was lower than that of muscles from healthy subjects and patients 
(fig. 79).  
 
Figure 79: Comparison of pink1 relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied; pink1 relative 
expression level is significantly different among liver and muscle, both from healthy subjects (p=0.0001) and from 
LLMI patients (p=0.0001) and between liver and adipose tissue (p=0.0001). Pink1 relative expression level is also 
significantly different among adipose tissue and muscles, both from healthy subjects (p=0.0001) and from LLMI 
patients (p=0.0001). 
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If genders were considered separately, the differences in pink1 expression levels among the 4 
groups were maintained both for females and males were the same he same as those that 
emerged from the total samples, as shown in fig. 80. 
 
Figure 80: Comparison of pink1 relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied. In the left 
panel are represented females: pink1 relative expression level is significantly different among liver and muscle, 
both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0002), between liver and adipose tissue 
(p=0.0010), among adipose tissue and muscle, both from healthy subjects (p=0.0001) and from LLMI patients 
(p=0.0001). In the right panel are represented males: pink1 relative expression level is significantly different 
among liver and muscle, both from healthy subjects (p=0.0046) and from LLMI patients (p=0.0004), between liver 
and adipose tissue (p=0.0002), among adipose tissue and muscle, both from healthy subjects (p=0.0015) and from 
LLMI patients (p=0.0001). 
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4.4.5.11 Beclin  
Similarly to polγ, twinkle, fis1 and pink1, the expression level of beclin was lower in adipose 
tissue with respect to muscles and to livers, that in turn expressed less beclin compared to 
muscles from healthy subjects and patients. Data can be observed in fig. 81. 
 
Figure 81: Comparison of beclin relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied; beclin relative 
expression level is significantly different among liver and muscle, both from healthy subjects (p=0.0002) and from 
LLMI patients (p=0.0001) and between liver and adipose tissue (p=0.0001). Beclin relative expression level is also 
significantly different among adipose tissue and muscle, both from healthy subjects (p=0.0001) and from LLMI 
patients (p=0.0001). 
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For females, the pattern of differences between the tissues was maintained when they were 
investigated alone, for male, instead, the expression level of beclin in liver was not significantly 
different from the expression level of the muscles of healthy subjects, while all the others 
dissimilarities were still significative, fig. 82. 
 
Figure 82: Comparison of beclin relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied. In the left 
panel are represented females: beclin relative expression level is significantly different among liver and muscle, 
both from healthy subjects (p=0.0003) and from LLMI patients (p=0.0009), between liver and adipose tissue 
(p=0.0001), among adipose tissue and muscle, both from healthy subjects (p=0.0001) and from LLMI patients 
(p=0.0001). In the right panel are represented males: beclin relative expression level is significantly different 
between liver and muscle from LLMI patients (p=0.0055), between liver and adipose tissue (p=0.0001), among 
adipose tissue and muscle, both from healthy subjects (p=0.0003) and from LLMI patients (p=0.0001). 
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4.4.5.12 Ambra  
Liver expressed less ambra than muscle (both from healthy subjects and from LLMI patients), 
but more than adipose tissue, that in turn, showed significant lower level of ambra than 
muscle, as showed in fig. 83. 
 
Figure 83: Comparison of ambra relative expression level among liver (0), muscle from healthy subjects (1), 
muscle from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied; ambra 
relative expression level is significantly different among liver and muscle, both from healthy subjects (p=0.0014) 
and from LLMI patients (p=0.0001) and between liver and adipose tissue (p=0.0001). Ambra relative expression 
level is also significantly different among adipose tissue and muscle, both from healthy subjects (p=0.0001) and 
from LLMI patients (p=0.0001). 
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In females, ambra expression levels were significative different between liver and muscle and 
between adipose tissue and muscle, but not between liver and adipose tissues, whereas in 
males, ambra expression level was significantly dissimilar between adipose tissue compared to 
liver and to muscle, but liver differed only to muscle from patients and not from healthy 
subjects (fig. 84). 
 
Figure 84: Comparison of ambra relative expression level among liver (0), muscle from healthy subjects (1), 
muscle from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied. In the 
left panel are represented females: ambra relative expression level is significantly different among liver and 
muscle, both from healthy subjects (p=0.0037) and from LLMI patients (p=0.0018), and among adipose tissue and 
muscle, both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0001). In the right panel are 
represented males: ambra relative expression level is significantly different between liver and muscle from LLMI 
patients (p=0.0040), between liver and adipose tissue (p=0.0037), and finally among adipose tissue and muscle, 
both from healthy subjects (p=0.0019) and from LLMI patients (p=0.0003). 
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4.4.5.13 Pik3cd 
In the expression level of pik3cd, some differences between tissues were found: muscles from 
LLMI patients showed lower expression levels with respect to muscles from healthy subjects, 
adipose tissues and livers, as shown in figure 85. These differences were completely lost when 
data were analyzed by gender (data not shown). 
 
Figure 85: Comparison of pik3cd relative expression level among liver (0), muscle from healthy subjects (1), 
muscle from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied; pik3cd 
relative expression level is significantly different between liver and muscle from LLMI patients (p=0.0018), 
between muscles from healthy subjects and from LLMI patients (p=0.0021) and between adipose tissue and 
muscle and from LLMI patients (p=0.0060). 
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4.4.5.14 Lonp 
A significative difference emerged between the expression level of lonp in liver and in muscle 
(for both the group of muscles considered), as well as for adipose tissue. Instead, no 
significative difference emerged between adipose tissue and liver.  
 
Figure 86: Comparison of lonp relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied; lonp relative 
expression level is significantly different among liver and muscle, both from healthy subjects (p=0.0001) and from 
LLMI patients (p=0.0001). Lonp relative expression level is also significantly different among adipose tissue and 
muscle, both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0001). 
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The same results emerged when gender were considered separately, as can be observed in 
figure 87. 
 
Figure 87: Comparison of lonp relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied. In the left 
panel are represented females: lonp relative expression level is significantly different among liver and muscle, 
both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0001) and among adipose tissue and muscle, 
both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0003). In the right panel are represented 
males: lonp relative expression level is significantly different among liver and muscle, both from healthy subjects 
(p=0.0003) and from LLMI patients (p=0.0001) and among adipose tissue and muscle, both from healthy subjects 
(p=0.0006) and from LLMI patients (p=0.0001). 
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4.4.5.15 Nos3 
A significative difference emerged in the expression level of nos3 between muscles from 
healthy subjects and from patients. The expression level of nos3 was higher in the former also 
than liver and adipose tissue, as can be seen in figure 88. 
 
Figure 88: Comparison of nos3 relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied; nos3 relative 
expression level is significantly different between muscle from healthy subjects and from LLMI patients 
(p=0.0003), and between muscle from healthy subjects and liver (p=0.0064). Nos3 relative expression level is also 
significantly different between adipose tissue and muscle from healthy subjects (p=0.0048). 
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When data were divided and analyzed by gender, these differences were still found significant 
in females, but not in males, that did not show any significant difference in the expression level 
of nos3 between the investigated tissues. 
 
Figure 89: Comparison of nos3 relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied. In the left 
panel are represented females: nos3 relative expression level is significantly different between muscle from 
healthy subjects and from LLMI patients (p=0.0002), between muscle from healthy subjects and liver (p=0.0018) 
and finally between muscle from healthy subjects and adipose tissue (p=0.0039). In the right panel are 
represented males: nos3 relative expression level is not significantly different among the 4 types of tissue. 
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4.4.5.16 Sod1  
The significant differences in the expression level of sod1 were found between liver and 
muscles, both from healthy subjects and from LLMI patients, and between adipose tissues and 
muscles, also in this case for both the groups of muscles. 
 
Figure 90: Comparison of sod1 relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied; sod1 relative 
expression level is significantly different among liver and muscle, both from healthy subjects (p=0.0001) and from 
LLMI patients (p=0.0001). Sod1 relative expression level is also significantly different among adipose tissue and 
muscle, both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0001). 
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Regarding the analysis by gender, some differences between females and males emerged. In 
particular, for females the same dissimilarities, showed in the total number of samples, were 
still significant, whereas for males, only the differences between liver and muscles from LLMI 
patients and between the latter and adipose tissue were still significantly diverse when data 
were divided, as demonstrated in figure 91. 
 
Figure 91: Comparison of sod1 relative expression level among liver (0), muscle from healthy subjects (1), muscle 
from LLMI patients (2) and adipose tissue (3). To compare tissues, Kruskal-Wallis test was applied. In the left 
panel are represented females: sod1 relative expression level is significantly different among liver and muscle, 
both from healthy subjects (p=0.0001) and from LLMI patients (p=0.0001) and among adipose tissue and muscle, 
both from healthy subjects (p=0.0010) and from LLMI patients (p=0.0008). In the right panel are represented 
males: sod1 relative expression level is significantly different between liver and muscle from LLMI patients 
(p=0.0010) and between adipose tissue and muscle from LLMI patients (p=0.0016). 
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5 Discussion 
Human aging is a highly complex process, comprising multiple mechanisms at different levels 
(Kirkwood, 2005). A general characteristic of aging is the systemic, chronic and low grade 
inflammation described as “inflamm-aging” (Franceschi et al., 2000), provoked by the 
persistence of inflammatory stimuli in answer to continuous antigenic load and stress 
(Morrissette-Thomas et al., 2014) and to the related accumulation of damaged 
macromolecules and cells (self-debris) (Franceschi and Campisi, 2014). Damage to 
biomolecules and to cellular components can be due to the excessive production of highly 
toxic reactive oxygen species (ROS), concept at the basis of the mitochondrial theory of aging, 
since mitochondria are the major intracellular producers of ROS (Chistiakov et al., 2014). This 
theory explains how a high ROS production leads to mtDNA mutations and deletions and thus 
to a decline in mitochondrial function with age (Harman, 1956). Moreover, as deleted mtDNA 
molecules increase in number, the level of ROS production becomes greater, inducing a vicious 
circle that enhances mitochondrial damages and eventually cell dysfunction (Wallace 2005). 
This phenomenon is more severe in post-mitotic tissues where the energy demand is 
particularly higher and the capability to eliminate damaged organelles progressively wanes 
(Salvioli et al., 2008). Data from literature suggest that metabolic or pathophysiological tissue 
properties may outline deletion specific fingerprints, basing on different mitotic activities, 
varied metabolic rates or exposure to specific genotoxins. Nevertheless, the tissue specific 
generation of deletions can be due also by tissue specific nuclear genes expression and nucleo-
mitochondrial interactions (Meissner et al., 2006).  
Moreover, in order to warrant oxidative capacity and cell survival it is therefore mandatory to 
maintain a sufficient number of intact mtDNA copies (Ylikallio et al., 2010), as well as the 
integrity of mitochondrial function, activity and appropriate morphology (Michel et al., 2012).  
Therefore, since in literature are present contrasting data regarding mtDNA rearrangements in 
different tissues, furthermore coming in a large part from model animals, and as less is known 
about the mechanisms that lead to tissue specific presence of mtDNA rearrangements, we 
focused our attention on three different human tissues. Thus, in our work we study mtDNA 
copy number, deletion level and integrity, as well as telomere length and the expression level 
of several genes involved in mitochondrial biogenesis, dynamics, protein degradation and 
mitophagy in order to understand if they are involved during aging of human liver, vastus 
lateralis skeletal muscle and adipose tissue.  
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However, to explain better our observations, data are discussed in four section: one for liver, 
one for skeletal muscle, one for adipose tissue and one dedicated to the comparison of the 
three different tissues. 
 
5.1 Liver 
In liver, what emerge from our data is that there is an increase in mtDNA copy number with 
age in human livers, while there is any change in mtDNA deletion level. However, when mtDNA 
deletion levels and copy number were examined together, independently of age, we found a 
strong correlation, from which results that as mtDNA copy number increases, mtDNA deletion 
level decreases. We called this ratio “mtDNA integrity”, representing the number of deleted 
molecules on the total number of mtDNA molecules presents in mitochondria and we found 
that it just slightly decreases with age. Therefore this data could suggest that deleted mtDNA 
copies has a replicative advantage compared to intact mtDNA copies (Wallace, 1989), but the 
increase in mtDNA copy number is likely a compensatory mechanism for defective 
mitochondria bearing mutated mtDNA. These data, in fact, are consistent with the previous 
study of Masuyama and colleagues on murine animal model in which they found an increase in 
mtDNA copy number during aging in several tissues of mice at different ages (Masuyama et al., 
2005).  
Telomere length was also investigated in our liver samples and as expected there is a 
significant telomere shortening during the aging of human liver. Besides, in 2011 Sahin and 
colleagues published a work in which they observed an association between telomere 
shortening and mitochondrial dysfunction, with a diminished expression of pgc-1α, that is a 
master regulator of mitochondrial biogenesis (Sahin et al., 2011).  
Interestingly, our data show how telomere attrition in liver is associated with an increase in 
mtDNA copy number and with a decrease in mtDNA deletion level and mtDNA integrity. As 
telomere shortening is a well-known marker of aging, we could hypothesize that liver mtDNA 
integrity is not preserved during aging, likely due to the activation of a compensatory 
mechanism regulating mtDNA copy number, that in turn increases to prevent a consecutive 
accumulation of deleted mtDNA molecules. 
This hypothesis is also sustained by the results coming from our gene expression analyses. In 
fact, we also analyzed the expression levels of some nuclear genes involved in several 
mitochondrial pathways, such as mitochondrial biogenesis (pgc-1α, polɣ, nrf1, tfam, twinkle, 
sirt1, sirt3, tomm40 and ppard), fusion and fission processes (mfn2, fis1 and opa1), mitophagy 
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(ambra1, beclin, pink1, parkin, atg16l and pik3cd), production of ROS (nos3), protection from 
ROS (sod1 and sod2), protein quality control system (lonp) and finally hypoxia (hif-1α), 
discovering that in all liver samples the expression level of some of these genes changes with 
age. In particular we observed an increment in the expression level of nrf1, that is involved in 
mitobiogenesis, of mfn2 and fis1, which are responsible for mitochondrial dynamism 
processes, and of lonp, than encodes for a mitochondrial protease. Therefore, the pathways 
that seem to be involved in the aging of human liver are those affected in mitochondrial 
quality control, which implies also a tight control of mtDNA copy number. Data from literature 
suggest the existence of a still unknown sensor of a lower or a higher threshold of mtDNA copy 
number leading to the activation of the replication machinery (biogenesis and fusion process) 
or of the degradation machinery (fission process and mitophagy) of mtDNA, respectively 
(Michel et al., 2012), as we can see in our samples. Moreover, Lon protease contributes to 
degradation of short-lived, misfolded or damaged proteins in mitochondria and is regulated by 
transcription factors associated to mitochondrial biogenesis and oxidative stress (Ngo et al, 
2013). 
What we can suppose is that during aging of human liver, a reduction, however small, of 
mtDNA integrity leads to increased expression of genes involved in the regulation of mtDNA 
copy number, that in turn increase as to compensate the damage.  
Therefore, even if our data on telomere shortening could indicate that liver ages, our data on 
mtDNA rearrangements suggest that they seem not to impinge upon macroscopic organ 
defects. In closing, it is worth noting that livers in this thesis are considered suitable for 
transplantation including that from very old donors, which are grafted in younger subjects with 
a successful outcome (Grazi et al., 2001; Cescon et al., 2003; Cescon et al., 2008).  
5.1.1 Gender difference in human liver aging 
Observing our data more deeply, a gender difference emerged, leading us to hypothesize that 
what we see in a global vision of liver is actually due to molecular mechanisms, which could act 
in a different way in females and males.  
In particular, in males mtDNA copy number increases with age, also in relation with telomere 
attrition. However, the increased expression level of nrf1 and lonp suggest that the 
mechanisms involved in the “compensatory pathway” are mitochondrial biogenesis and the 
protein quality control system, without changes in mitochondrial dynamics. Nevertheless, 
these mechanisms are still sufficient to maintain regulated mtDNA rearrangements, without 
impairment of mitochondrial functions.  
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Instead, in liver biopsies from female’s donors we did not find any change in mtDNA 
rearrangements during aging, as well as any association with telomere shortening, that instead 
increases with age. Also the expression level of nrf1, fis1 (that instead do not change in males) 
and lonp increases with age in females, suggesting that the involvement of fission process 
added to mitochondrial biogenesis and the protein quality control system allows mtDNA copy 
number to be highly regulated and to avoid mtDNA rearrangements. This is supported by 
literature data reporting that, promoting mitochondrial fission, mitochondrial dysfunction 
partially reverts (Liu et al., 2011), since mitochondrial quality and integrity are maintained 
selecting dysfunctional mitochondria (Chistiakov et al., 2014).  
At the end, either for males and females, the increase of expression level of lonp could have a 
beneficial effect, seeing that conversely in rat the age-related downregulation of Lon protease 
has detrimental effect, not allowing the degradation of oxidized proteins (Ngo et al.,2013). 
Moreover, from these data come out that the expression level of lonp and nrf1 increase with 
age and this is particularly important since the protein encoded by nrf1 gene is critical to 
expression of genes encoding proteasomal subunit (Oh et al., 2013), while lonp encodes the 
main mitochondrial protease. Thus, these data fit perfectly with data of Bellavista and 
colleagues coming out from experiments performed on the same liver biopsies that show how 
efficient proteostasis and proteasome are maintained with age (Bellavista et al., 2014).  
 
5.2 Skeletal muscle 
The progressive and age-associated decline in skeletal muscle mass, strength and function was 
defined by Roseberg as sarcopenia (Roseberg, 1989), and its leads to reduced endurance 
capacity and increased muscle fatigability, that in turn may contribute to increase frailty and 
greater risk of falls (Cruz-Jentoft, 2010; Fielding et al., 2011).  
Since skeletal muscle is one of the tissue with high energy demand and mitochondria carry out 
pivotal functions in the context of energy provision, many studies focus on the role of 
mitochondria in sarcopenia, suggesting that mtDNA rearrangements are one of the major 
causes. Nevertheless, literature data about this topic are often controversial (Peterson et al., 
2012; Johnson et al., 2013). 
Thus, in our study we focused on the analysis of mtDNA rearrangements in order to better 
characterize and understand the involvement of the mitochondrion in skeletal muscle aging 
and sarcopenia. To reach this goal, we studied mtDNA copy number, deletion level and 
integrity, as well as telomere shortening and the expression level of several nuclear genes, in 
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vastus lateralis biopsies from two different groups of subjects at different ages: healthy 
subjects and lower limb mobility impairment (LLMI) patients. 
5.2.1 Healthy subjects 
Consistently with the work of Welle and colleagues (Welle et al., 2003), our data from the 
group of healthy subjects suggest that mtDNA copy number decreases with age, even if in a 
barely significant way, while no significative change emerges in mtDNA deletion level. 
Moreover, during physiological aging of human skeletal muscle, mtDNA integrity shows a 
marked reduction with age. This decline of mtDNA integrity with age is consistent with 
literature data, which report an increase in mutation and oxidative damages on mtDNA with 
age (Kazachkova et al., 2013). Indeed, with advancing age there is a well established decline in 
mitochondrial activity, due to mtDNA damage caused by an increase in ROS production and to 
the mtDNA proximity to the source of ROS, in addition to its lack of introns and its weak DNA 
repair systems. These lacks can facilitate the accumulation of mtDNA mutation and 
rearrangements, that could be provoked during mtDNA replication, but, above all, can occur in 
genes coding for ETC subunits or at control sites. In this way, a sort of damage-propagating 
loop is generated, further worsening mitochondrial activity and enhancing ROS production. 
Thereby mtDNA rearrangements have been associated to muscle mass loss, weakness and 
sarcopenia (Johnson et al., 2013). 
Besides mtDNA rearrangements, also telomere length has been investigated in our vastus 
lateralis muscle biopsies from healthy subjects, as the majority of the literature data consider 
this parameter as a biomarker of aging and longevity, reporting a decrease in telomere length 
with age. However, we did not find any significative change in telomere length in healthy 
skeletal muscle, like reported by the study of Ponsot and colleagues in 2008 (Ponsot et al., 
2008). In addition to this, we did not find significant relations among mtDNA rearrangements 
and telomere shortening, suggesting us that the relation is not direct and other mechanisms 
could affect mitochondrial dysfunction. 
To characterize more deeply the involvement of mitochondria and mtDNA rearrangements in 
the aging of human skeletal muscle, the relative expression level of genes involved in 
mitobiogenesis (pgc-1α, polɣ, nrf1, tfam, twinkle, sirt1, sirt3, tomm40 and ppard), fusion and 
fission processes (mfn2, fis1 and opa1), mitophagy (ambra1, beclin, pink1, parkin, atg16l and 
pik3cd), production of ROS (nos3), protection from ROS (sod1 and sod2), protein quality 
control system (lonp) and finally hypoxia (hif-1α), was also evaluated. What we observed is a 
general decrease in the expression level of pgc-1α, polɣ, tfam, opa1, beclin and pik3cd, that 
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suggest how, during the physiological aging of skeletal muscle, some mechanisms can be 
impaired.  
In particular, these data are consistent with that present in literature, reporting a decline in 
mitochondrial activity and dynamics with aging, due to accumulation of mtDNA damages and 
ROS overproduction. Specifically, the majority of studies performed on both skeletal muscle in 
humans and rodents report a decrease in mitochondrial biogenesis with reduction of pgc-1α 
and tfam expression level (Ling et al., 2004; Lanza et al., 2008; Safdar et al., 2010; Koltai et al., 
2012). Moreover, also the downregulation of fusion process has been detected in muscle of 
subjects affected by type-2-diabetes and obesity, which are associated with accelerated 
development and/or progression of sarcopenia. In particular, depletion of opa1, that is a 
mitochondrial fusion factor, disintegrates the mitochondrial network and sensitizes cultured 
cell to apoptosis (Marzetti et al, 2013). Finally, also mitophagy has been reported to decline 
with age with consequent accumulation of dysfunctional mitochondrial and oxidative damage 
that may contribute to muscle loss and sarcopenia (Peterson et al., 2012; Johnson et al., 2013; 
Marzetti et al., 2013).  
Hence, our results are in accordance with mitochondrial data present in literature, suggesting 
that during physiological aging, skeletal muscle is affected by mitochondrial DNA 
rearrangements which are due to the reduction of mitochondrial biogenesis and to the 
impairment of the fusion and autophagy processes.  
5.2.1.1  Gender difference in aging of skeletal muscle from healthy subjects 
As for the liver, also in the case of skeletal muscle vastus lateralis, a gender difference emerges 
during aging, regarding mtDNA modifications and above all the expression level of the 
considered genes.  
In particular, in males mtDNA integrity decreases with age, as well as the expression level of 
pgc-1α, polɣ, opa1, pik3cd and nos3. These data lead us to speculate that the diminished 
expression of some of the pivotal factor of mitochondrial biogenesis, fusion and mitophagy is 
rather as a deficiency in the activation of a compensatory mechanism, which leads to the 
establishment of the damage-propagating loop at the basis of mitochondrial dysfunction and, 
likely, of sarcopenia.  
This is enhanced in females samples, where the reduction in the expression level of pgc-1α, 
tfam, and beclin is sufficient to induce not only a decrease in mtDNA integrity, but also a light 
increase in mtDNA deletion, as to indicate that are precisely mitochondrial biogenesis and 
autophagy the key processes to the maintenance of mitochondrial function.  
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Even if the actors that change with age are different between females and males, our data are 
consistent with those present in literature, where several studies report how, mitochondrial 
density decline gradually during skeletal muscle aging, due to an age-dependent reduction of 
pgc-1α and thus of mitochondrial biogenesis (Wenz et al., 2009). Moreover, it is reported that 
also mitophagy declines with aging, leading to an accumulation of aberrant mitochondria 
(Mammuccari and Rizzuto, 2010), how happens in our samples. 
5.2.2 LLMI patients 
During muscle disuse due to lower limb mobility impairment, the scenario is quite similar to 
that of physiological aging: mtDNA copy number and mtDNA integrity markedly decrease with 
age, while no changes emerge in mtDNA deletion level.  
Also for telomere length, we found that there are no changes with age and any direct relation 
among telomere shortening and mtDNA rearrangements is present, even if mitochondria are 
the most important source of ROS and a connection between the role of mitochondria and 
oxidative stress in telomere-driven replicative senescence has been proposed (von Zglinicki et 
al., 2001; Saretzki and von Zglinicki, 2002; Passos et al., 2007; Ahmend et al., 2008; Sahin and 
DePinho, 2012). 
The gene expression analysis, instead, shows how different mechanisms are involved in the 
pathological aging process of skeletal muscle. In particular, in this group there is an increase in 
sirt1 expression level, that could be related to an increase in mitochondrial biogenesis, since 
sirt1 promoted the deacetylation of pgc-1α, leading to its activation (Houtkooper et al., 2012). 
However we conversely observed a decrease in mtDNA copy number, as to indicate that the 
increment in sirt1 is not sufficient to deacetylate enough pgc-1α, inducing mitobiogenesis. 
Moreover, there is a decrease in the expression level of beclin, pink1 and sod1, as to indicate 
that also in the case of muscle disuse, aging is driven by deregulated mitophagy, in addition to 
a reduced capacity to contrast ROS production. As for the reduction in mitophagy activation, 
also the diminished expression level of sod1 is in agreement with what reported in literature, 
since Watanabe described how sod1-/- mice showed significant age-dependent decrease in the 
whole hind limb muscle mass, inducing skeletal muscle atrophy (Watanabe et al., 2014). 
5.2.2.1 Gender difference in aging of skeletal muscle from LLMI patients 
How expected, also in the case of muscle atrophy due to hospitalization, a gender difference 
emerged, either for mtDNA rearrangements and genes expression level. 
In particular, in males mtDNA copy number and integrity decrease with age, while the mtDNA 
deletion level increases. This is accompanied by a diminution of the expression level of sod1, 
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that is one of the main antioxidant enzymes present in cells. The sod1 deficiency in muscle was 
previously demonstrated as responsible of the O2•- intracellular enhancement that leads to 
increased oxidative damage and induces aberrant mitochondria with lower ATP production 
(Watanabe et al., 2014). Therefore these data lead us to suppose that the diminished mtDNA 
copy number, in addition to the increment of mtDNA deletion level, is due to the decrease 
expression level of sod1 without the activation of any compensatory mechanism. 
What happens in females is different, since there is a reduction in the expression level of tfam, 
pink1 and beclin without any changes in mtDNA copy number, deletion level and integrity. 
Some years ago, Dagda and colleagues observed that a loss of regulation of mitophagy, with a 
consecutive increase of this process, results in increased mtDNA degradation, that has been 
implicated in human disease such as Parkinson’s disease (Dagda et al., 2008). Hence, it is 
plausible that to maintain the present complete mtDNA molecules, without new mitochondrial 
biogenesis, that it is also diminished, also mitophagy is kept to low levels, in order to escape 
the degradation of intact mtDNA.  
 
5.3 Adipose tissue 
Even if the importance of white adipose tissue (WAT) is increasing more and more as an 
endocrine organ responsible for energy intake, energy expenditure, and insulin resistance, 
literature data about WAT mitochondria in aging are still poor of evidences. It is known that 
with age, white adipocytes reduce their mitochondrial content (Kusminski and Scherer, 2012), 
and that a decreased expression of key regulators of mitochondrial biogenesis have been 
described in type-2-diabetes patients (van Tienen et al., 2010), which, as age-related disease, 
could indicate what happen in a harmful aging process. Hence, what emerge from our data is 
quite new but at the same time, controversial in respect to literature. Indeed, mtDNA copy 
number, deletion level and integrity did not show any change with age in our samples.  
What is known in literature regarding the telomere shortening in adipose tissue is that it is 
significantly associated with hypertrophy adipocytes, low circulating adiponectin levels and 
impaired glucose and lipid metabolism in individual either with obesity and type-2-diabetis. 
Moreover, in subcutaneous adipose tissue, telomere length is negatively associated with age 
(Lakowa et al, 2015). However, in our samples telomere length did not vary with age, probably 
because, as suggested by Spalding and colleagues, mature adipocytes have relatively low 
renewal rate and it is known that telomere shorten when cell proliferate (Spalding et al., 
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2008). Additionally, we did not find any relation between telomere length and mtDNA 
parameters.  
However, different variations in genes expression level were found in our samples. In 
particular, among the genes considered, we detected an increase in twinkle, nrf1, pink1, 
ambra, nos3 and sod1 expression level. Since little is known about the regulation of 
mitochondrial processes in adipose tissues, from these data we can speculate that, like in liver, 
the increased expression of these genes is like a sort of activation of a compensatory 
mechanism which lead at the end to the lack of changes in mtDNA copy number, deletion level 
and integrity.  
Though, based on a study of van Tienen and colleagues where it is showed how in mouse 3T3-
L1 cultured cells overexpression of nrf1 can induce directly inflammation in adipocytes (van 
Tienen et al., 2010), another speculation is plausible. From literature, in fact, it is known that 
WAT is one of the most important players in the establishment of metaflammation (Gregor 
and Hotamisligil, 2011), and that the latter contributes to the systemic phenomenon of 
inflammaging (Cevenini et al., 2013). Thus we could hypothesize that, with age, the increased 
expression of nrf1 causes an augmented release of inflammatory mediators and, in this way, 
an elevated nos3 expression and ROS production, which in turn could raise the expression level 
of those genes involved in the mitochondrial quality control and ROS scavenger processes. 
Besides, this seems to happen only in females, since in males there are no changes either in 
mtDNA rearrangements or in gene expression level. Probably this gender difference is caused 
by the different metabolic function of adipose tissue in women with respect to men, in 
addition to a dissimilar distribution. In particular, women have higher subcutaneous adipose 
tissue compared to men, which instead have high level of visceral adipose tissue. This 
difference is related to the influence of sex hormones, but also to the diverse function of 
subcutaneous adipose tissue in women, which is important to support lactation, and the 
visceral adipose tissue in males, that serves as readily mobilizable deposition to facilitate rapid 
burst of energy (Palmer and Clegg, 2015).  
 
5.4 Tissue comparison 
As aging is tissue specific, also mitochondrial respiration capacity and mtDNA copy number are 
not random, but rather specific to tissue type and to developmental stage (Clay Montier, 
2009). In 1988, Robin and Wong observed that the numbers of mitochondria vary among 
different cell types and that the amount of mtDNA per mitochondrion is constant in all cell 
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types, measuring both the virtual mitochondrial number and the mtDNA amount per 
mitochondrion in different cell types (Robin and Wong, 1988). Later, several studies were 
performed both in human and in animal model to assess the mtDNA abundance in terminally 
differentiated tissues, such as brain, skeletal muscle and heart, in relation to age (Herbert et 
al., 2011).  
In our work, we had the possibility to compare mtDNA copy number, deletion level and 
integrity, as well as telomere length and the expression level of nuclear genes involved in 
mitochondrial pathways among three different human tissues, independently of age. What 
emerge by our data is that no differences appear in telomere length and mtDNA deletion level 
among the three tissues, but in liver mtDNA copy number and integrity are lower than in 
skeletal muscle and adipose tissue. These data are consistent with the recent work of D’Erchia 
and colleagues, which measured mtDNA copy number in six human tissue types (brain, lung, 
kidney, liver, heart and skeletal muscle) from three unrelated individuals, founding that in 
heart and skeletal muscle mtDNA copy number is higher than in liver (D’Erchia et al., 2015).  
Moreover, in our case, it is to underlie that nevertheless liver has the lowest mtDNA copy 
number and mtDNA integrity, it has the highest expression level of tfam and opa1, that are 
genes involved in mitochondrial biogenesis and fusion process. It is to note that mitochondrial 
biogenesis and fusion process can affect directly mtDNA copy number, suggesting that they 
are involved in cellular adaptation to environmental stimuli and in physiological activity. Also 
the expression level of pik3cd is different among the considered tissues, as to indicate that also 
autophagy is tissue-specifically regulated. Instead, all the other genes (pgc-1α, polγ, nrf1, 
twinkle, sirt1, mfn2, fis1, pink1, beclin, ambra, lonp, nos3 and sod1) are more expressed in 
skeletal muscle than in liver and adipose tissue. These data of gene expression, together with 
the high amount of mtDNA in skeletal muscle, are in agreement with those of D’Erchia and 
colleagues, that measured also the respiratory capacity of the tissues considered, founding 
that skeletal muscle and heart have the highest one (D’Erchia et al., 2015). 
Thus, even if we are only at the beginning of a comprehensive and age-independent vision of 
tissue-related variability in mtDNA, from this comparison is quite clear that mtDNA copy 
number and integrity as well as the expression level of nuclear genes involved in mitochondrial 
pathways are strictly linked to metabolic and bioenergetics tissue demands.  
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6 Conclusions 
The involvement of mitochondria and mtDNA rearrangements in human aging is still an open 
and debated issue, which is based on controversial data from different groups. The results 
presented in this thesis represent a first attempt to study the involvement of mitochondrial 
rearrangements, intended as mtDNA copy number, deletion level and integrity, from a tissue-
specific point of view, studying three different human tissues: liver, skeletal muscle and 
adipose tissue. 
From the results obtained in this study on biopsies of liver, we can presume that the decrease 
in mtDNA integrity is accompanied with an increase in mtDNA copy number, suggesting the 
existence of a “compensatory mechanism” that it is able to maintain the functionality of liver. 
The gene expression analysis, in fact, revealed that with age there is an increase in the 
expression level of those nuclear genes involved in mitochondrial biogenesis, mitochondrial 
dynamic processes and mitochondrial protein quality control system, suggesting that these 
mechanisms represent the “compensatory pathway” activated in liver aging. Supporting this 
hypothesis, it is to be considered that the biopsies utilized in this study were taken from 
organs considered suitable for transplantation and liver from very old donors were grafted in 
younger subjects with a successful outcome. 
Different is the case of vastus lateralis muscle of which we had two groups of subjects at 
different ages, healthy subjects and patients with muscle disuse due to hip osteoarthritis 
(leading to hip replacement). Effectively from the muscle results we can conclude that, since 
mtDNA integrity and copy number decrease with age both in healthy subjects and in patients, 
during muscle aging any “compensatory pathway” is activated, leading to the well-known 
phenomenon of sarcopenia. Indeed, conversely from the liver, the gene expression analysis 
shows a reduced level of the genes involved in mitochondrial biogenesis and autophagy. 
We also studied white adipose tissue coming from the same subjects with muscle disuse, 
knowing that during aging there is an accumulation of inter-muscular adipose tissue. From 
literature less is known about the aging of this tissue, but it is known that it contributes to the 
metaflammation process and, in this way, to the more complex phenomenon of inflammaging. 
Our data suggest us that mtDNA rearrangements in adipose tissue do not incur in changes with 
advancing age, but from the results of the gene expression analysis, we can deduce two 
different hypotheses. The former is that the increased expression of the genes considered 
represent, like for liver, the activation of the compensatory mechanism that allows any 
mitochondrial changes. Instead the latter is that the increased expression of the genes 
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considered could be due to the involvement of the chronic, low grade inflammatory response 
that is common in human aging. 
 
Figure 92: mtDNA rearrangements during aging of three different human tissues, such as liver, skeletal muscle 
and white adipose tissue. In the circular boxes there are observed data, whereas in rectangular boxes there are 
our hypotheses. 
We analyzed also the telomere length in these different tissues, as in literature it is reported as 
a good marker of aging. However, while in liver there was a significantly decrease in telomere 
length with advancing age, no changes were observed in skeletal muscle and adipose tissue. 
These results lead us to conclude that, as proposed by Martin-Ruiz and colleagues, telomere 
length is more a risk indicator than a marker of aging (Martin-Ruiz et al., 2014) and that, as for 
mtDNA rearrangements, also the telomere length is tissue specific.  
Since we started this work in order to study the tissue specificity of mtDNA rearrangements, 
we finally compared the mtDNA copy number, deletion level and integrity, as well as the gene 
expression levels among the different tissues, independently from age. From the comparison 
results we can conclude that metabolic and bioenergetics tissue demands are fundamental 
aspects regulating mitochondrial functionality and activity.  
What is extremely peculiar in our work is that for all tissues a markedly gender difference 
appears either in mtDNA rearrangements or in gene expression levels. As far as we know, 
literature reports studies performed in humans and animal models without any particular 
attention to gender. Thus this thesis can be the starting point to study how mtDNA 
rearrangements differently affect aging in males and females. 
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